Header Logo

NITIN JAIN

TitleAssistant Professor
InstitutionMD Anderson
DepartmentLeukemia
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Short NJ, Jabbour E, Nasr LF, Jain N, Haddad FG, Issa GC, Sasaki K, Senapati J, Kebriaei P, Garris R, Konopleva M, Ravandi F, Kantarjian H. Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy. Am J Hematol. 2024 Apr 12. PMID: 38607091.
      Citations:    
    2. Huang X, Li Y, Zhang J, Yan L, Zhao H, Ding L, Bhatara S, Yang X, Yoshimura S, Yang W, Karol SE, Inaba H, Mullighan C, Litzow M, Zhu X, Zhang Y, Stock W, Jain N, Jabbour E, Kornblau SM, Konopleva M, Pui CH, Paietta E, Evans W, Yu J, Yang JJ. Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia. Cancer Cell. 2024 Apr 08; 42(4):552-567.e6. PMID: 38593781; PMCID: PMC11008188.
      Citations:    
    3. Bose P, Masarova L, Pemmaraju N, Bledsoe SD, Daver NG, Jabbour EJ, Kadia TM, Estrov Z, Kornblau SM, Andreeff M, Jain N, Cortes JE, Borthakur G, Alvarado Y, Richie MA, Dobbins MH, McCrackin SA, Zhou L, Pierce SA, Wang X, Pike AM, Garcia-Manero G, Kantarjian HM, Verstovsek S. Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study. Haematologica. 2024 Apr 04. PMID: 38572554.
      Citations:    Fields:    
    4. Zhao Y, Short NJ, Kantarjian HM, Chang TC, Ghate PS, Qu C, Macaron W, Jain N, Thakral B, Phillips A, Khoury JD, Garcia-Manero G, Zhang W, Fan Y, Yang H, Garris R, Nasr LF, Kriwacki R, Roberts KG, Konopleva MY, Jabbour EJ, Mullighan CG. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. Blood. 2024 Mar 29. PMID: 38551807.
      Citations:    Fields:    
    5. Kittai AS, Bond D, Huang Y, Bhat SA, Blyth E, Byrd JC, Chavez JC, Davids MS, Dela Cruz JP, Dowling MR, Duffy C, Ho C, Jacobson C, Jaglowski S, Jain N, Lin KH, Miller C, McCarthy C, Omer Z, Parry E, Rai M, Rogers KA, Saha A, Schachter L, Scott H, Senapati J, Shadman M, Siddiqi T, Stephens DM, Vanguru V, Wierda W, Woyach JA, Thompson PA. Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study. J Clin Oncol. 2024 Mar 29; JCO2400033. PMID: 38552193.
      Citations:    Fields:    
    6. Hampel PJ, Swaminathan M, Rogers KA, Parry EM, Burger JA, Davids MS, Ding W, Ferrajoli A, Hyak JM, Jain N, Kenderian SS, Wang Y, Wierda WG, Woyach JA, Parikh SA, Thompson PA. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia. Blood Adv. 2024 Mar 27. PMID: 38537065.
      Citations:    Fields:    
    7. Hooper N, Marathe A, Jain NB, Jayaram P. Cell-Based Therapies for Rotator Cuff Injuries: An Updated Review of the Literature. Int J Mol Sci. 2024 Mar 08; 25(6). PMID: 38542113; PMCID: PMC10970404.
      Citations:    Fields:    Translation:HumansAnimals
    8. Bazinet A, Garcia-Manero G, Short N, Alvarado Y, Bataller A, Abuasab T, Islam R, Montalbano K, Issa G, Maiti A, Yilmaz M, Jain N, Masarova L, Kornblau S, Jabbour E, Montalban-Bravo G, Rausch CR, Pierce S, DiNardo CD, Kadia T, Daver N, Konopleva M, Huang X, Kantarjian H, Ravandi F. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study. Lancet Haematol. 2024 Apr; 11(4):e276-e286. PMID: 38452788.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    9. Short NJ, Jabbour EJ, Jain N, Senapati J, Nasr LF, Haddad FG, Li Z, Hsiao YC, Yang JJ, Pemmaraju N, Ohanian M, Wierda WG, Montalban-Bravo G, Borthakur G, Han L, Xiao L, Huang X, Abramova R, Zhao M, Garris R, Konopleva M, Ravandi F, Kantarjian HM, Short NJ, Jabbour E, Jain N, Senapati J, Nasr L, Haddad FG, Li Z, Hsiao YC, Yang JJ, Pemmaraju N, Ohanian M, Wierda WG, Montalban-Bravo G, Borthakur G, Han L, Xiao L, Huang X, Abramova R, Zhao M, Garris R, Konopleva M, Ravandi F, Kantarjian H. A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia. Blood Adv. 2024 Feb 27; 8(4):909-915. PMID: 38207208; PMCID: PMC10875259.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    10. Khouri IF, Alzahrani K, Kantarjian H, Milton DR, Gulbis AM, Sasaki K, Jain N, Short NJ, Kadia T, Daher M, Rafei H, Im JS, Marin D, Olson AL, Popat U, Qazilbash M, Ramdial J, Rondon G, Srour S, Kebriaei P, Shpall E, Champlin R, Jabbour EJ. Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial. Am J Hematol. 2024 May; 99(5):836-843. PMID: 38400519; PMCID: PMC11001510.
      Citations:    Fields:    
    11. Jain N, Croner LJ, Allan JN, Siddiqi T, Tedeschi A, Badoux XC, Eckert K, Cheung LWK, Mukherjee A, Dean JP, Szafer-Glusman E, Seymour JF. Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax. Clin Cancer Res. 2024 02 01; 30(3):498-505. PMID: 37955424; PMCID: PMC10831330.
      Citations: 2     Fields:    Translation:Humans
    12. Jabbour EJ, Haddad FG, Short NJ, Senapati J, Jain N, Sasaki K, Jorgensen JL, Wang SA, Alvarado Y, Wang X, DiNardo CD, Masarova L, Kadia TM, Garris R, Ravandi F, Kantarjian HM, Jabbour E, Haddad FG, Short NJ, Senapati J, Jain N, Sasaki K, Jorgensen J, Wang SA, Alvarado Y, Wang X, DiNardo C, Masarova L, Kadia T, Garris RS, Ravandi F, Kantarjian H. Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood. 2024 Feb 01; 143(5):417-421. PMID: 37879077.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    13. Senapati J, Kantarjian H, Haddad FG, Short NJ, Welch MA, Jain N, Jabbour E. SOHO State of the Art Updates and Next Questions | Next Questions: Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2024 Jan 08. PMID: 38195323.
      Citations:    Fields:    
    14. Tian Z, Shi C, Yang G, Allen JK, Shi Q, Al-Shami A, Olson JW, Smith MG, Chang Q, Kaur J, You J, Lofton TE, Gonzalez MA, Zhang Q, Zha D, Tasian SK, Jain N, Konopleva MY, Heffernan T, Molldrem JJ. Correction: Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL. Leukemia. 2024 Jan; 38(1):226. PMID: 38036631; PMCID: PMC10776386.
      Citations:    Fields:    
    15. Short NJ, Jabbour E, Jamison T, Paul S, Cuglievan B, McCall D, Gibson A, Jain N, Haddad FG, Nasr LF, Marx KR, Rausch C, Savoy JM, Garris R, Ravandi F, Kantarjian H. Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2024 04; 24(4):e168-e173. PMID: 38212207.
      Citations:    Fields:    Translation:HumansCells
    16. Haddad FG, Jabbour E, Short NJ, Jain N, Kantarjian H. SOHO State of the Art Updates and Next Questions: Update on the Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2023 Dec 14. PMID: 38185587.
      Citations:    Fields:    
    17. Zhao Y, Short NJ, Kantarjian HM, Chang TC, Ghate PS, Qu C, Macaron W, Jain N, Thakral B, Phillips AH, Khoury J, Garcia-Manero G, Zhang W, Fan Y, Yang H, Garris RS, Nasr LF, Kriwacki RW, Roberts KG, Konopleva M, Jabbour EJ, Mullighan CG. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. medRxiv. 2023 Dec 09. PMID: 38106221; PMCID: PMC10723521.
      Citations:    
    18. Senapati J, Fiskus WC, Daver N, Wilson NR, Ravandi F, Garcia-Manero G, Kadia T, DiNardo CD, Jabbour E, Burger J, Short NJ, Alvarado Y, Jain N, Masarova L, Issa GC, Qiao W, Khoury JD, Pierce S, Miller D, Sasaki K, Konopleva M, Bhalla KN, Borthakur G, Pemmaraju N. Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clin Cancer Res. 2023 11 01; 29(21):4352-4360. PMID: 37585491.
      Citations:    Fields:    Translation:Humans
    19. Jia Y, Han L, Ramage CL, Wang Z, Weng CC, Yang L, Colla S, Ma H, Zhang W, Andreeff M, Daver N, Jain N, Pemmaraju N, Bhalla K, Mustjoki S, Zhang P, Zheng G, Zhou D, Zhang Q, Konopleva M. Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells. Haematologica. 2023 10 01; 108(10):2626-2638. PMID: 37078252; PMCID: PMC10542840.
      Citations:    Fields:    Translation:HumansCells
    20. Sasaki K, Haddad FG, Short NJ, Jain N, Issa G, Jabbour E, Kantarjian H. Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, and End Results database, 2000-2019. Cancer. 2023 12 01; 129(23):3805-3814. PMID: 37769040.
      Citations: 1     Fields:    Translation:HumansCells
    21. Parry EM, Lemvigh CK, Deng S, Dangle N, Ruthen N, Knisbacher BA, Bros?us J, Hergalant S, Gui?ze R, Li S, Zhang W, Johnson C, Yin S, Werner L, Anandappa A, Purroy N, Gohil S, Oliveira G, Bachireddy P, Shukla SA, Huang T, Khoury JD, Thakral B, Dickinson M, Tam C, Livak KJ, Getz G, Neuberg D, Feugier P, Kharchenko P, Wierda W, Olsen LR, Jain N, Wu CJ, Long JM. ZNF683 marks a CD8+ T?cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome. Cancer Cell. 2023 10 09; 41(10):1803-1816.e8. PMID: 37738974; PMCID: PMC10618915.
      Citations: 2     Fields:    Translation:HumansCells
    22. Kadia TM, Ravandi F, Molica M, Bataller A, Borthakur G, Daver N, Jabbour E, DiNardo CD, Pemmaraju N, Jain N, Ferrajoli A, Ylimaz M, Bose P, Tidwell RS, Marx KR, Rausch CR, Kanagal-Shamanna R, Wang S, Islam R, Champlin R, Shpall E, Konopleva M, Garcia-Manero G, Kantarjian H. Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. Am J Hematol. 2023 11; 98(11):1711-1720. PMID: 37635400.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    23. Tian Z, Shi C, Yang G, Allen JK, Shi Q, Ai-Shami A, Olson JW, Smith MG, Chang Q, Kaur J, You J, Lofton TE, Gonzalez MA, Zhang Q, Zha D, Tasian SK, Jain N, Konopleva MY, Heffernan T, Molldrem JJ, Al-Shami A. Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL. Leukemia. 2023 10; 37(10):2006-2016. PMID: 37634013; PMCID: PMC10539166.
      Citations:    Fields:    Translation:HumansAnimalsCells
    24. Pasvolsky O, Kebriaei P, Shah BD, Jabbour E, Jain N. Chimeric antigen receptor T-cell therapy for adult B-cell acute lymphoblastic leukemia: state-of-the-(C)ART and the road ahead. Blood Adv. 2023 07 25; 7(14):3350-3360. PMID: 36912764; PMCID: PMC10345854.
      Citations:    Fields:    Translation:HumansCells
    25. Haddad FG, Sasaki K, Bidikian A, Issa GC, Kadia T, Jain N, Alvarado Y, Short NJ, Pemmaraju N, Loghavi S, Patel KP, Kanagal-Shamanna R, Yilmaz M, Masarova L, Jabbour E, Kantarjian H. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. Am J Hematol. 2023 10; 98(10):1619-1626. PMID: 37485584.
      Citations:    Fields:    Translation:Humans
    26. Short NJ, Muftuoglu M, Ong F, Nasr L, Macaron W, Montalban-Bravo G, Alvarado Y, Basyal M, Daver N, Dinardo CD, Borthakur G, Jain N, Ohanian M, Jabbour E, Issa GC, Qiao W, Huang X, Kanagal-Shamanna R, Patel KP, Bose P, Ravandi F, Delumpa R, Abramova R, Garcia-Manero G, Andreeff M, Cortes J, Kantarjian H. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. J Hematol Oncol. 2023 07 08; 16(1):73. PMID: 37422688; PMCID: PMC10329789.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    27. Strati P, Gregory T, Majhail NS, Jain N. Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies: A Practical Review. JCO Oncol Pract. 2023 09; 19(9):706-713. PMID: 37406255.
      Citations: 1     Fields:    Translation:Humans
    28. Olesinski EA, Bhatia KS, Mahesh AN, Rosli S, Mohamed JS, Jen WY, Jain N, Garcia JS, Wong GC, Ooi M, Letai A, Konopleva M, Bhatt S. BH3 profiling identifies BCL-2 dependence in adult patients with early T-cell progenitor acute lymphoblastic leukemia. Blood Adv. 2023 06 27; 7(12):2917-2923. PMID: 36763538; PMCID: PMC10285538.
      Citations: 1     Fields:    Translation:HumansCells
    29. Roccograndi LM, Lovell AR, Ferrajoli A, Thompson PA, Burger JA, Wierda WG, Jain N, Rausch CR. Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation. Leuk Lymphoma. 2023 09; 64(9):1554-1561. PMID: 37317991.
      Citations:    Fields:    Translation:Humans
    30. Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, Basu S, Kadia T, Daver N, Borthakur G, Konopleva M, Pemmaraju N, Parry E, Wu CJ, Khoury J, Bueso-Ramos C, Garg N, Wang X, Lopez W, Ayala A, O'Brien S, Kantarjian H, Keating M, Allison J, Sharma P, Wierda W. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Adv. 2023 05 23; 7(10):1958-1966. PMID: 36287248; PMCID: PMC10189379.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    31. Short NJ, Jabbour E, Macaron W, Ravandi F, Jain N, Kanagal-Shamanna R, Patel KP, Loghavi S, Haddad FG, Yilmaz M, Issa GC, Kebriaei P, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Kantarjian H. Ultrasensitive NGS MRD assessment in Ph+?ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1. Am J Hematol. 2023 08; 98(8):1196-1203. PMID: 37183966.
      Citations:    Fields:    Translation:Humans
    32. Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Montalban Bravo G, Sasaki K, Kadia TM, Khoury J, Wang SA, Haddad FG, Jacob J, Garris R, Ravandi F, Kantarjian HM. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol. 2023 Jun; 10(6):e433-e444. PMID: 37187201.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    33. Thompson PA, Keating MJ, Ferrajoli A, Jain N, Peterson CB, Garg N, Wang SA, Jorgensen JL, Kadia TM, Bose P, Pemmaraju N, Short NJ, Wierda WG. Venetoclax consolidation in high-risk CLL treated with ibrutinib for =1 year achieves a high rate of undetectable MRD. Leukemia. 2023 07; 37(7):1444-1453. PMID: 37138019.
      Citations:    Fields:    Translation:Humans
    34. Kantarjian H, Haddad FG, Jain N, Sasaki K, Short NJ, Loghavi S, Kanagal-Shamanna R, Jorgensen J, Khouri I, Kebriaei P, Alvarado Y, Kadia T, Paul S, Garcia-Manero G, Dabaja B, Yilmaz M, Jacob J, Garris R, O'Brien S, Ravandi F, Jabbour E. Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia. J Hematol Oncol. 2023 05 02; 16(1):44. PMID: 37131217; PMCID: PMC10155451.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    35. Senapati J, Jabbour E, Konopleva M, Short NJ, Tang G, Daver N, Kebriaei P, Kadia T, Pemmaraju N, Takahashi K, DiNardo C, Sasaki K, Borthakur G, Thakral B, Kanagal-Shamanna R, Patel K, Ravandi F, Roberts K, Mullighan C, Kantarjian H, Jain N. Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements. JCO Precis Oncol. 2023 05; 7:e2200707. PMID: 37196217; PMCID: PMC10309573.
      Citations:    Fields:    Translation:HumansCells
    36. Yoshimura S, Panetta JC, Hu J, Li L, Gocho Y, Du G, Umezawa A, Karol SE, Pui CH, Mullighan CG, Konopleva M, Stock W, Teachey DT, Jain N, Yang JJ. Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia. Leukemia. 2023 06; 37(6):1194-1203. PMID: 37076694; PMCID: PMC10347458.
      Citations:    Fields:    Translation:HumansAnimalsCells
    37. Gordon MJ, Jones JE, George B, Peterson C, Burger JA, Jain N, Keating M, Wierda WG, Durand JB, Ferrajoli A. Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity. Cancer. 2023 07 15; 129(14):2192-2200. PMID: 37016930; PMCID: PMC10882584.
      Citations:    Fields:    Translation:Humans
    38. Desikan SP, Senapati J, Jabbour E, Abuasab T, Short N, Tang G, Wang S, Kebriaei P, Kadia T, Borthakur G, Ravandi F, Roberts K, Mullighan C, Konopleva M, Kantarjian H, Jain N. Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B-cell acute lymphoblastic leukemia. Am J Hematol. 2023 06; 98(6):E142-E144. PMID: 36877196.
      Citations:    Fields:    Translation:Humans
    39. Jabbour E, Short NJ, Jain N, Haddad FG, Welch MA, Ravandi F, Kantarjian H. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades. J Hematol Oncol. 2023 03 16; 16(1):22. PMID: 36927623; PMCID: PMC10018889.
      Citations: 4     Fields:    Translation:HumansCells
    40. El Hussein S, Medeiros LJ, Gruschkus SK, Wei P, Schlette E, Fang H, Jelloul FZ, Wang W, Fiskus W, Kanagal-Shamanna R, Loghavi S, Yang H, Li S, Xu J, Tang Z, Thakral B, Jain N, Wierda WG, Patel K, Bhalla KN, Khoury JD. Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma?variant. Virchows Arch. 2023 Jun; 482(6):1011-1019. PMID: 36864257.
      Citations:    Fields:    Translation:HumansCells
    41. Ayers GD, Atem F, Jain NB, Thakur B, DeClercq JJ. Statistical and Methodological Considerations for Randomized Controlled Trial Design in Physical Medicine and Rehabilitation. Am J Phys Med Rehabil. 2023 10 01; 102(10):855-860. PMID: 36882301; PMCID: PMC10471787.
      Citations:    Fields:    Translation:Humans
    42. El Hussein S, Medeiros LJ, Lyapichev KA, Fang H, Jelloul FZ, Fiskus W, Chen J, Wei P, Schlette E, Xu J, Li S, Kanagal-Shamanna R, Yang H, Tang Z, Thakral B, Loghavi S, Jain N, Thompson PA, Ferrajoli A, Wierda WG, Jabbour E, Patel KP, Dabaja BS, Bhalla KN, Khoury JD. Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma. Pathology. 2023 Jun; 55(4):514-524. PMID: 36933995.
      Citations:    Fields:    Translation:Humans
    43. Jabbour EJ, Sasaki K, Haddad FG, Issa GC, Garcia-Manero G, Kadia TM, Jain N, Yilmaz M, DiNardo CD, Patel KP, Kanagal-Shamanna R, Champlin R, Khouri IF, Dellasala S, Pierce SA, Kantarjian H. The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors. Am J Hematol. 2023 04; 98(4):658-665. PMID: 36683287.
      Citations: 1     Fields:    Translation:Humans
    44. Sasaki K, Ravandi F, Kadia TM, Borthakur G, Short NJ, Jain N, Daver NG, Jabbour EJ, Garcia-Manero G, Loghavi S, Patel KP, Montalban-Bravo G, Masarova L, DiNardo CD, Kantarjian HM. Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia. Cancer. 2023 04 01; 129(7):1017-1029. PMID: 36715486.
      Citations: 1     Fields:    Translation:Humans
    45. Parry EM, Leshchiner I, Gui?ze R, Johnson C, Tausch E, Parikh SA, Lemvigh C, Bros?us J, Hergalant S, Messer C, Utro F, Levovitz C, Rhrissorrakrai K, Li L, Rosebrock D, Yin S, Deng S, Slowik K, Jacobs R, Huang T, Li S, Fell G, Redd R, Lin Z, Knisbacher BA, Livitz D, Schneider C, Ruthen N, Elagina L, Taylor-Weiner A, Persaud B, Martinez A, Fernandes SM, Purroy N, Anandappa AJ, Ma J, Hess J, Rassenti LZ, Kipps TJ, Jain N, Wierda W, Cymbalista F, Feugier P, Kay NE, Livak KJ, Danysh BP, Stewart C, Neuberg D, Davids MS, Brown JR, Parida L, Stilgenbauer S, Getz G, Wu CJ. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Nat Med. 2023 01; 29(1):158-169. PMID: 36624313; PMCID: PMC10155825.
      Citations: 5     Fields:    Translation:Humans
    46. Kantarjian H, Short NJ, Jain N, Sasaki K, Huang X, Haddad FG, Khouri I, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Kebriaei P, Garris R, Loghavi S, Jorgensen J, Kwari M, O'Brien S, Ravandi F, Jabbour E. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol. 2023 03; 98(3):493-501. PMID: 36600670.
      Citations: 1     Fields:    Translation:HumansCells
    47. Pirri C, Stecco C, G?vener O, Mezian K, Ricci V, Jacisko J, Novotn? T, Kara M, Chang KV, Dughbaj M, Jain NB, ?z?akar L. EURO-MUSCULUS/USPRM Dynamic Ultrasound Protocols for Knee. Am J Phys Med Rehabil. 2023 05 01; 102(5):e67-e72. PMID: 36729007.
      Citations: 2     Fields:    Translation:Humans
    48. Dupouy S, Marchiq I, Derippe T, Almena-Carrasco M, Jozwik A, Fouliard S, Adimy Y, Geronimi J, Graham C, Jain N, Maus MV, Mohty M, Boissel N, Teshima T, Kato K, Benjamin R, Balandraud S. Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia. Cancer Res Commun. 2022 11; 2(11):1520-1531. PMID: 36970059; PMCID: PMC10035397.
      Citations: 2     Translation:HumansCells
    49. Boddu PC, Senapati J, Ravandi-Kashani F, Jabbour EJ, Jain N, Ayres M, Chen Y, Keating MJ, Kantarjian HM, Gandhi V, Kadia TM. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies. Cancer. 2023 02 15; 129(4):580-589. PMID: 36448227.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    50. Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KH, Kanagal-Shamanna R, Khoury JD, Patel K, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Haddad FG, Kwari M, Thankachan J, Delumpa R, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2022 Nov 16. PMID: 36402146.
      Citations: 13     Fields:    
    51. Cutler HS, DeClercq J, Ayers GD, Serbin P, Jain N, Khazzam M. Risk of Revision Shoulder Arthroplasty After Anatomic and Reverse Total Shoulder Arthroplasty. J Am Acad Orthop Surg. 2023 Jan 01; 31(1):17-25. PMID: 36548151.
      Citations: 1     Fields:    
    52. Jabbour E, Short NJ, Jain N, Thompson PA, Kadia TM, Ferrajoli A, Huang X, Yilmaz M, Alvarado Y, Patel KP, Garcia-Manero G, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2022 Dec; 9(12):e878-e885. PMID: 36279879.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    53. Marx KR, Rausch CR, Lovell AR, Short NJ, Paul S, Jain N, Lee J, Savoy JM, Ravandi F, Jabbour E. Incidence of adverse effects in patients receiving ponatinib with concomitant azole antifungals. Leuk Lymphoma. 2023 01; 64(1):79-86. PMID: 36222579.
      Citations:    Fields:    Translation:HumansCells
    54. Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, Yallop D, Konopleva M, Frigault MJ, Teshima T, Kato K, Boucaud F, Balandraud S, Gianella-Borradori A, Binlich F, Marchiq I, Dupouy S, Almena-Carrasco M, Pannaux M, Fouliard S, Brissot E, Mohty M, CALM Study Group. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. Lancet Haematol. 2022 Nov; 9(11):e833-e843. PMID: 36228643.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    55. Saini NY, Swoboda DM, Greenbaum U, Ma J, Patel RD, Devashish K, Das K, Tanner MR, Strati P, Nair R, Fayad L, Ahmed S, Lee HJ, Iyer SP, Steiner R, Jain N, Nastoupil L, Loghavi S, Tang G, Bassett RL, Jain P, Wang M, Westin JR, Green MR, Sallman DA, Padron E, Davila ML, Locke FL, Champlin RE, Garcia-Manero G, Shpall EJ, Kebriaei P, Flowers CR, Jain MD, Wang F, Futreal AP, Gillis N, Neelapu SS, Takahashi K. Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. Blood Cancer Discov. 2022 09 06; 3(5):385-393. PMID: 35533245; PMCID: PMC9445749.
      Citations:    Fields:    
    56. Jabbour E, Sasaki K, Haddad FG, Issa GC, Skinner J, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Garcia-Manero G, Takahashi K, Borthakur G, Pemmaraju N, Pierce S, Kantarjian H. Low-dose dasatinib 50?mg/day versus standard-dose dasatinib 100?mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol. 2022 Nov; 97(11):1413-1418. PMID: 36054032.
      Citations:    
    57. Jain N, Chin HM, Mani H, Lupo C, Nikolic DS, Kordts A, Pirandola S, Pedersen TB, Kolb M, ?mer B, Pacher C, Gehring T, Andersen UL. Practical continuous-variable quantum key distribution with composable security. Nat Commun. 2022 Aug 12; 13(1):4740. PMID: 35961965; PMCID: PMC9374721.
      Citations:    
    58. Pemmaraju N, Wilson NR, Senapati J, Economides MP, Guzman ML, Neelapu SS, Kazemimood R, Davis RE, Jain N, Khoury JD, Sugita M, Cai T, Smith J, Frattini MG, Garton A, Roboz G, Konopleva M. CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights. Leuk Res. 2022 10; 121:106928. PMID: 35963025.
      Citations:    
    59. Short NJ, Kantarjian H, Ravandi F, Konopleva M, Jain N, Kanagal-Shamanna R, Patel KP, Macaron W, Kadia TM, Wang S, Jorgensen JL, Khoury JD, Yilmaz M, Kebriaei P, Takahashi K, Garcia-Manero G, Daver N, Post SM, Huang X, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Jabbour E. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv. 2022 07 12; 6(13):4006-4014. PMID: 35533262; PMCID: PMC9278301.
      Citations:    Fields:    Translation:Humans
    60. Jabbour EJ, Short NJ, Jain N, Jammal N, Jorgensen J, Wang S, Wang X, Ohanian M, Alvarado Y, Kadia T, Sasaki K, Garris R, Garcia-Manero G, Ravandi F, Kantarjian HM. Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higher. Am J Hematol. 2022 Sep; 97(9):1135-1141. PMID: 35713551.
      Citations:    Fields:    
    61. Desikan SP, Ravandi F, Pemmaraju N, Konopleva M, Loghavi S, Jabbour EJ, Daver N, Jain N, Chien KS, Maiti A, Montalban-Bravo G, Kadia TM, Macaron W, DeLumpa R, Kwari M, Borthakur G, Short NJ. A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations. Acta Haematol. 2022; 145(5):529-536. PMID: 35717939.
      Citations:    Fields:    
    62. Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, Daver NG, DiNardo CD, Sasaki K, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Ferrajoli A, Bhalla KN, Jabbour E, Takahashi K, Malla R, Quagliato K, Kanagal-Shamanna R, Popat UR, Andreeff M, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol. 2022 11 20; 40(33):3848-3857. PMID: 35704787; PMCID: PMC9671758.
      Citations:    Fields:    
    63. Paul S, Kantarjian H, Sasaki K, Marx K, Jain N, Savoy JM, DiPippo A, Jammal N, Bravo GM, Kadia T, Garcia-Manero G, Short NJ, Ravandi F, Jabbour E. Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Am J Hematol. 2023 01; 98(1):E11-E14. PMID: 35633516.
      Citations:    Fields:    
    64. Mezian K, Ricci V, G?vener O, Jacisko J, Novotn? T, Kara M, Chang KV, Nanka O, Pirri C, Stecco C, Dughbaj M, Jain NB, ?z?akar L. EURO-MUSCULUS/USPRM Dynamic Ultrasound Protocols for (Adult) Hip. Am J Phys Med Rehabil. 2022 11 01; 101(11):e162-e168. PMID: 35687784.
      Citations:    Fields:    
    65. Berkman AM, Andersen CR, Cuglievan B, McCall DC, Lupo PJ, Parsons SK, DiNardo CD, Short NJ, Jain N, Kadia TM, Livingston JA, Roth ME. Long-Term Outcomes among Adolescent and Young Adult Survivors of Acute Leukemia: A Surveillance, Epidemiology, and End Results Analysis. Cancer Epidemiol Biomarkers Prev. 2022 06 01; 31(6):1176-1184. PMID: 35553621; PMCID: PMC9179079.
      Citations:    Fields:    Translation:Humans
    66. Cherng HJ, Khwaja R, Kanagal-Shamanna R, Tang G, Burger J, Thompson P, Ferrajoli A, Estrov Z, Sasaki K, Sampath D, Wang X, Kantarjian H, Keating M, Wierda WG, Jain N. TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis. Am J Hematol. 2022 08; 97(8):1005-1012. PMID: 35567779; PMCID: PMC9354943.
      Citations:    Fields:    Translation:Humans
    67. DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Kadia T, Daver N, Xiao L, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Bravo GM, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol. 2022 08; 97(8):1035-1043. PMID: 35583199.
      Citations: 1     Fields:    Translation:Humans
    68. Pemmaraju N, Wilson NR, Garcia-Manero G, Sasaki K, Khoury JD, Jain N, Borthakur G, Ravandi F, Daver N, Kadia T, DiNardo C, Jabbour E, Pierce S, Qazilbash M, Konopleva M, Kantarjian H. Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. Blood Adv. 2022 05 24; 6(10):3027-3035. PMID: 35061885; PMCID: PMC9131912.
      Citations: 1     Fields:    Translation:HumansCells
    69. Rozovski U, Veletic I, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Verstovsek S, Keating MJ, Estrov Z. STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells. J Immunol. 2022 06 15; 208(12):2847-2855. PMID: 35595309; PMCID: PMC9308680.
      Citations:    Fields:    Translation:HumansCells
    70. Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Maiti A, Jabbour E, Jain N, Issa G, Takahashi K, Sasaki K, Ohanian M, Pierce S, Tang G, Loghavi S, Patel K, Wang SA, Garcia-Manero G, Andreeff M, Ravandi F, Daver N. Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J. 2022 05 02; 12(5):77. PMID: 35501304; PMCID: PMC9061716.
      Citations:    Fields:    Translation:Humans
    71. Sasaki Y, Kantarjian HM, Short NJ, Wang F, Furudate K, Uryu H, Garris R, Jain N, Sasaki K, Ravandi F, Konopleva M, Garcia-Manero G, Little L, Gumbs C, Zhao L, Futreal PA, Takahashi K, Jabbour E. Correction: Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia. 2022 May; 36(5):1448. PMID: 35411096.
      Citations:    Fields:    
    72. Kim K, Konopleva M, DiNardo CD, Borthakur G, Loghavi S, Tang G, Daver N, Pemmaraju N, Jabbour E, Rausch CR, Yilmaz M, Sasaki K, Short NJ, Jain N, Brandt M, Pierce S, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. Am J Hematol. 2022 07; 97(7):885-894. PMID: 35413152.
      Citations:    Fields:    Translation:Humans
    73. Sasaki K, Ravandi F, Kadia T, DiNardo C, Borthakur G, Short N, Jain N, Daver N, Jabbour E, Garcia-Manero G, Khoury J, Konoplev S, Loghavi S, Patel K, Montalban-Bravo G, Masarova L, Konopleva M, Kantarjian H. Prediction of survival with intensive chemotherapy in acute myeloid leukemia. Am J Hematol. 2022 07; 97(7):865-876. PMID: 35384048.
      Citations:    Fields:    Translation:Humans
    74. Haddad FG, Sasaki K, Issa GC, Garcia-Manero G, Ravandi F, Kadia T, Cortes J, Konopleva M, Pemmaraju N, Alvarado Y, Yilmaz M, Borthakur G, DiNardo C, Jain N, Daver N, Short NJ, Jabbour E, Kantarjian H. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. Am J Hematol. 2022 07; 97(7):856-864. PMID: 35357036.
      Citations: 1     Fields:    Translation:Humans
    75. Grusky AZ, Giri A, O'Hanlon D, Jain NB. The Relationship of Aging and Smoking With Rotator Cuff Disease: A Systematic Review and Meta-analysis. Am J Phys Med Rehabil. 2022 04 01; 101(4):331-340. PMID: 34121068; PMCID: PMC8665931.
      Citations:    Fields:    Translation:Humans
    76. Gaballa MR, Banerjee P, Jiang X, Ganesh C, Khazal S, Nandivada V, Islam S, Kaplan M, Daher M, Basar R, Alousi A, Mehta R, Alatrash G, Khouri I, Oran B, Marin D, Popat U, Olson A, Tewari P, Jain N, Jabbour E, Ravandi F, Kantarjian H, Chen K, Champlin R, Shpall E, Rezvani K, Kebriaei P, Milton DR. Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia. Blood. 2022 03 24; 139(12):1908-1919. PMID: 34914826; PMCID: PMC8952188.
      Citations: 3     Fields:    Translation:Humans
    77. Jelloul FZ, Yang R, Garces S, Kanagal-Shamanna R, Ok CY, Loghavi S, Routbort MJ, Zuo Z, Yin CC, Floyd K, Bassett RL, Wierda W, Jain N, Thompson P, Luthra R, Medeiros LJ, Patel KP. Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia. Leuk Res. 2022 05; 116:106827. PMID: 35430388; PMCID: PMC9185699.
      Citations:    Fields:    Translation:Humans
    78. Short NJ, Macaron W, Konopleva M, Ravandi F, Jain N, Issa GC, Kadia T, Sasaki K, Kebriaei P, Yilmaz M, Thompson PA, Takahashi K, Abbas HA, Wierda WG, Garris R, Kantarjian HM, Jabbour E. Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. Am J Hematol. 2022 06 01; 97(6):E201-E204. PMID: 35266566.
      Citations:    Fields:    Translation:HumansCells
    79. Chang KV, Mezian K, Kara M, Stecco C, Pirri C, Ata AM, Dughbaj M, Jain NB, Ricci V, G?vener O, Leblebicioglu G, ?z?akar L. EURO-MUSCULUS/USPRM Dynamic Ultrasound Protocols for Shoulder. Am J Phys Med Rehabil. 2022 03 01; 101(3):e29-e36. PMID: 34923500.
      Citations:    Fields:    Translation:Humans
    80. Mukherjee A, Jabbour EJ, Gulbis AM, Kadia T, Jain N, Ledesma C, Burger J, Ferrajoli A, Wierda W, Medeiros LJ, Kantarjian H, Champlin R, Khouri IF, Milton DR. Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors. Leuk Lymphoma. 2022 04; 63(4):885-893. PMID: 35225133; PMCID: PMC9730341.
      Citations:    Fields:    Translation:Humans
    81. Yi X, Jain N, Iles LR, Ayres ML, Wierda WG, Gandhi V. Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia. Front Oncol. 2022; 12:833714. PMID: 35273915; PMCID: PMC8901605.
      Citations:    
    82. Mato AR, Davids MS, Sharman J, Roeker LE, Kay N, Kater AP, Rogers K, Thompson MC, Rhodes J, Goy A, Skarbnik A, Schuster SJ, Tam CS, Eyre TA, O'Brien S, Nabhan C, Lamanna N, Sun C, Shadman M, Pagel JM, Ujjani C, Brander D, Coombs CC, Jain N, Cheah CY, Brown JR, Seymour JF, Woyach JA. Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare). Clin Cancer Res. 2022 02 15; 28(4):603-608. PMID: 34789482; PMCID: PMC9253788.
      Citations: 1     Fields:    Translation:Humans
    83. Sasaki Y, Kantarjian HM, Short NJ, Wang F, Furudate K, Uryu H, Garris R, Jain N, Sasaki K, Ravandi F, Konopleva M, Garcia-Manero G, Little L, Gumbs C, Zhao L, Futreal PA, Takahashi K, Jabbour E. Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia. 2022 05; 36(5):1253-1260. PMID: 35132195.
      Citations:    Fields:    Translation:HumansCells
    84. Jelloul FZ, Yang RK, Wang P, Garces S, Kanagal-Shamanna R, Ok CY, Loghavi S, Routbort MJ, Zuo Z, Yin CC, Floyd K, Bassett RL, Wierda WG, Jain N, Thompson PA, Luthra R, Medeiros LJ, Patel KP. Non-coding NOTCH1 mutations in chronic lymphocytic leukemia negatively impact prognosis. Am J Hematol. 2022 03 01; 97(3):E100-E102. PMID: 34989420; PMCID: PMC9034465.
      Citations: 1     Fields:    Translation:Humans
    85. Gibson A, Trabal A, McCall D, Khazal S, Toepfer L, Bell DH, Roth M, Mahadeo KM, Nunez C, Short NJ, DiNardo C, Konopleva M, Issa GC, Ravandi F, Jain N, Borthakur G, Kantarjian HM, Jabbour E, Cuglievan B. Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancers (Basel). 2021 Dec 29; 14(1). PMID: 35008312; PMCID: PMC8750927.
      Citations: 2     
    86. Chang KV, Wu WT, Mezian K, Kara M, Pirri C, Ata AM, Dughbaj M, Jain NB, Stecco C, Ricci V, G?vener O, Leblebicioglu G, ?z?akar L. EURO-MUSCULUS/USPRM Dynamic Ultrasound Protocols for Elbow. Am J Phys Med Rehabil. 2022 06 01; 101(6):e83-e92. PMID: 34930863.
      Citations:    Fields:    Translation:Humans
    87. Sivina M, Kim E, Wierda WG, Ferrajoli A, Jain N, Thompson P, Kantarjian H, Keating M, Burger JA. Ibrutinib induces durable remissions in treatment-na?ve patients with CLL and 17p deletion and/or TP53 mutations. Blood. 2021 12 16; 138(24):2589-2592. PMID: 34521099; PMCID: PMC8832441.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    88. Richard-Carpentier G, Kantarjian HM, Tang G, Yin CC, Khoury JD, Issa GC, Haddad F, Jain N, Ravandi F, Short NJ, DiNardo CD, Takahashi K, Konopleva MY, Daver NG, Kadia T, Garcia-Manero G, Garris R, O'Brien S, Jabbour E. Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience. Blood Adv. 2021 12 14; 5(23):5415-5419. PMID: 34525185; PMCID: PMC9153023.
      Citations:    Fields:    Translation:Humans
    89. Sasaki K, Kadia T, Begna K, DiNardo CD, Borthakur G, Short NJ, Jain N, Daver N, Jabbour E, Garcia-Manero G, Bravo GM, Masarova L, Pierce S, Konopleva M, Ravandi F, Tefferi A, Kantarjian H. Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. Am J Hematol. 2022 01 01; 97(1):68-78. PMID: 34716921.
      Citations:    Fields:    Translation:Humans
    90. Samra B, Khoury JD, Morita K, Ravandi F, Richard-Carpentier G, Short NJ, El Hussein S, Thompson P, Jain N, Kantarjian H, Jabbour E. Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse. Blood Adv. 2021 10 26; 5(20):3913-3918. PMID: 34464974; PMCID: PMC8945626.
      Citations:    Fields:    Translation:Humans
    91. Ramos Perez JM, Patel KP, Loghavi S, Garcia-Manero G, Borthakur G, Jabbour E, Wierda W, Pierce S, Brandt M, Kornblau S, Kadia T, Daver N, DiNardo CD, Jain N, Yilmaz M, Short N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Rivera D, McCue D, Kantarjian HM, Ravandi F. Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. Leuk Lymphoma. 2022 03; 63(3):672-675. PMID: 34668451.
      Citations:    Fields:    Translation:Humans
    92. Pemmaraju N, Wilson NR, Khoury JD, Jain N, Daver N, Pierce S, Jabbour E, Kadia T, DiNardo C, Garcia-Manero G, Qazilbash M, Konopleva M, Kantarjian H. Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. Blood. 2021 10 14; 138(15):1373-1377. PMID: 34098573.
      Citations: 2     Fields:    Translation:HumansCells
    93. Kantarjian HM, Jain N, Garcia-Manero G, Welch MA, Ravandi F, Wierda WG, Jabbour EJ. The cure of leukemia through the optimist's prism. Cancer. 2022 01 15; 128(2):240-259. PMID: 34614211; PMCID: PMC8738114.
      Citations:    Fields:    Translation:Humans
    94. Niswander LM, Loftus JP, Pondrom M, Hottman DA, Iacobucci I, Mullighan CG, Jain N, Konopleva M, Tasian SK, Lainey ?, Caye-Eude A, Cav? H, Baruchel A, Rohrlich PS. Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia. Haematologica. 2021 10 01; 106(10):2763-2767. PMID: 34196168; PMCID: PMC8485673.
      Citations: 1     Fields:    Translation:HumansCells
    95. Brown PA, Shah B, Advani A, Aoun P, Boyer MW, Burke PW, DeAngelo DJ, Dinner S, Fathi AT, Gauthier J, Jain N, Kirby S, Liedtke M, Litzow M, Logan A, Luger S, Maness LJ, Massaro S, Mattison RJ, May W, Oluwole O, Park J, Przespolewski A, Rangaraju S, Rubnitz JE, Uy GL, Vusirikala M, Wieduwilt M, Lynn B, Berardi RA, Freedman-Cass DA, Campbell M. Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 09 20; 19(9):1079-1109. PMID: 34551384.
      Citations: 6     Fields:    Translation:HumansCells
    96. Dall TM, Reynolds RL, Chakrabarti R, Forte GJ, Langelier M, Wang S, Whyte J, Sridhara Ankam N, Annaswamy TM, Fredericson M, Jain NB, Perret Karimi D, Morgenroth DC, Slocum C, Wisotzky E. The Physiatry Workforce in 2019 and Beyond, Part 2: Modeling Results. Am J Phys Med Rehabil. 2021 09 01; 100(9):877-884. PMID: 33278133.
      Citations: 1     Fields:    Translation:Humans
    97. Forte GJ, Langelier M, Wang S, Dall TM, Reynolds RL, Chakrabarti R, Whyte J, Ankam NS, Annaswamy TM, Fredericson M, Jain NB, Karimi DP, Morgenroth DC, Slocum C, Wisotzky E. The Physiatry Workforce in 2019 and Beyond, Part 1: Results From a Cross-sectional Survey. Am J Phys Med Rehabil. 2021 09 01; 100(9):866-876. PMID: 33443853.
      Citations:    Fields:    Translation:Humans
    98. Jain N. Evolving Treatment Paradigm in Frontline CLL. JCO Oncol Pract. 2022 02; 18(2):114-115. PMID: 34449250.
      Citations:    Fields:    Translation:Humans
    99. Pemmaraju N, Carter BZ, Bose P, Jain N, Kadia TM, Garcia-Manero G, Bueso-Ramos CE, DiNardo CD, Bledsoe S, Daver NG, Popat U, Konopleva MY, Zhou L, Pierce S, Estrov ZE, Borthakur GM, Ohanian M, Qiao W, Masarova L, Wang X, Mak PY, Cortes J, Jabbour E, Verstovsek S. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv. 2021 08 24; 5(16):3163-3173. PMID: 34424319; PMCID: PMC8405193.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    100. Chien KS, Kim K, Nogueras-Gonzalez GM, Borthakur G, Naqvi K, Daver NG, Montalban-Bravo G, Cortes JE, DiNardo CD, Jabbour E, Alvarado Y, Andreeff M, Bose P, Jain N, Kadia TM, Huang X, Sheppard KB, Klingner-Winton C, Pierce SA, Dong XQ, Soltysiak KA, Kantarjian HM, Garcia-Manero G. Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. Br J Haematol. 2021 11; 195(3):378-387. PMID: 34340254.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    101. Kadia TM, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y, Dinardo CD, Daver N, Jain N, Pemmaraju N, Short N, Wang SA, Tidwell RSS, Islam R, Konopleva M, Garcia-Manero G, Ravandi F, Kantarjian HM. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2021 Aug; 8(8):e552-e561. PMID: 34329576; PMCID: PMC8884174.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    102. Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol. 2021 Aug 01; 7(8):1213-1219. PMID: 34110383; PMCID: PMC8193546.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    103. Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, DiNardo CD, Kadia T, Garcia-Manero G, Ohanian M, Daver N, Konopleva M, Pemmaraju N, Ferrajoli A, Andreeff M, Jain N, Estrov Z, Jabbour EJ, Wierda WG, Pierce S, Pinsoy MR, Xiao L, Ravandi F, Cortes JE. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica. 2021 08 01; 106(8):2121-2130. PMID: 33853292; PMCID: PMC8327731.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    104. Jabbour E, Patel K, Jain N, Duose D, Luthra R, Short NJ, Zugmaier G, San Lucas A, Velasco K, Tran Q, Zaman F, Konopleva M, Kantarjian H. Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER study. Am J Hematol. 2021 10 01; 96(10):E379-E383. PMID: 34161631.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    105. Sasaki K, Kantarjian HM, Morita K, Short NJ, Konopleva M, Jain N, Ravandi F, Garcia-Manero G, Wang S, Khoury JD, Jorgensen JL, Champlin RE, Khouri IF, Kebriaei P, Schroeder HM, Khouri M, Garris R, Takahashi K, O'Brien SM, Jabbour EJ. Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2021 09 15; 127(18):3381-3389. PMID: 34138471.
      Citations: 1     Fields:    Translation:HumansCells
    106. Byrd JC, Woyach JA, Furman RR, Martin P, O'Brien S, Brown JR, Stephens DM, Barrientos JC, Devereux S, Hillmen P, Pagel JM, Hamdy A, Izumi R, Patel P, Wang MH, Jain N, Wierda WG. Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood. 2021 06 17; 137(24):3327-3338. PMID: 33786588; PMCID: PMC8670015.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    107. Thakral B, Jain N, Tang G, Konoplev S, Vega F, Medeiros LJ, Wang SA. From the archives of MD Anderson Cancer Center: Concurrent BCR-ABL1 and CRLF2 rearrangements in B-lymphoblast phase of chronic myeloid leukemia. Ann Diagn Pathol. 2021 Aug; 53:151767. PMID: 34118580.
      Citations:    Fields:    Translation:HumansCells
    108. Jain N. How I manage chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2021 Jun; 19(6):360-364. PMID: 34106909.
      Citations:    Fields:    Translation:Humans
    109. Jain N, Maiti A, Ravandi F, Konopleva M, Daver N, Kadia T, Pemmaraju N, Short N, Kebriaei P, Ning J, Cortes J, Jabbour E, Kantarjian H. Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. Am J Hematol. 2021 08 01; 96(8):1000-1007. PMID: 33991360; PMCID: PMC9096877.
      Citations: 2     Fields:    Translation:HumansCells
    110. DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol. 2021 09 01; 39(25):2768-2778. PMID: 34043428; PMCID: PMC8407653.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    111. Kadia TM, Ravandi F, Borthakur G, Konopleva M, DiNardo CD, Daver N, Pemmaraju N, Kanagal-Shamanna R, Wang X, Huang X, Pierce S, Rausch C, Burger J, Ferrajoli A, Jain N, Popat U, Estrov Z, Verstovsek S, Jabbour E, Garcia-Manero G, Kantarjian H. Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2021 08 01; 96(8):914-924. PMID: 33901324.
      Citations: 4     Fields:    Translation:Humans
    112. Cherng HJ, Jain N. First-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both? Hematol Oncol Clin North Am. 2021 08; 35(4):725-738. PMID: 34174983; PMCID: PMC9185694.
      Citations:    Fields:    Translation:Humans
    113. Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. 2021 12; 35(12):3421-3429. PMID: 34007049.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    114. Cherng HJ, Jammal N, Paul S, Wang X, Sasaki K, Thompson P, Burger J, Ferrajoli A, Estrov Z, O'Brien S, Keating M, Wierda WG, Jain N. Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia. Br J Haematol. 2021 07; 194(1):61-68. PMID: 33973230; PMCID: PMC9284944.
      Citations: 1     Fields:    Translation:Humans
    115. Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv. 2021 04 13; 5(7):1876-1883. PMID: 33792630; PMCID: PMC8045494.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    116. Short NJ, Konopleva M, Kadia T, Kebriaei P, Daver N, Huang X, Masarova L, Cook R, Jain N, Jabbour E, Kantarjian H, Ravandi F. An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol. 2021 07 01; 96(7):E229-E232. PMID: 33780038; PMCID: PMC9278812.
      Citations: 4     Fields:    Translation:HumansCells
    117. Morita K, Kantarjian HM, Sasaki K, Issa GC, Jain N, Konopleva M, Short NJ, Takahashi K, DiNardo CD, Kadia TM, Garcia-Manero G, Daver N, Montalban Bravo G, Cortes JE, Ravandi F, Jabbour E. Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. Cancer. 2021 08 01; 127(15):2641-2647. PMID: 33823073.
      Citations: 4     Fields:    Translation:HumansCells
    118. Sasaki K, Jabbour E, Short NJ, Jain N, Ravandi F, Pui CH, Kantarjian H. Acute lymphoblastic leukemia: A population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017. Am J Hematol. 2021 06 01; 96(6):650-658. PMID: 33709456; PMCID: PMC9517941.
      Citations: 5     Fields:    Translation:HumansCellsPHPublic Health
    119. Sasaki K, Kantarjian HM, Short NJ, Samra B, Khoury JD, Kanagal Shamanna R, Konopleva M, Jain N, DiNardo CD, Khouri R, Garcia-Manero G, Kadia TM, Wierda WG, Khouri IF, Kebriaei P, Mehta RS, Champlin RE, Garris R, Cheung CM, Daver N, Thompson PA, Yilmaz M, Ravandi F, Jabbour E. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer. 2021 08 01; 127(15):2648-2656. PMID: 33793964.
      Citations: 3     Fields:    Translation:HumansCells
    120. Grusky AZ, Song A, Kim P, Ayers GD, Higgins LD, Kuhn JE, Baumgarten KM, Matzkin E, Jain NB. Factors Associated With Symptomatic Rotator Cuff Tears: The Rotator Cuff Outcomes Workgroup Cohort Study. Am J Phys Med Rehabil. 2021 04 01; 100(4):331-336. PMID: 33443862; PMCID: PMC7969413.
      Citations: 3     Fields:    Translation:Humans
    121. Koller P, Saliba RM, Ledesma C, Rondon G, Popat U, Alousi A, Mehta R, Oran B, Olson A, Hosing C, Qazilbash M, Khouri I, Ciurea S, Shpall E, Jorgensen J, Wang S, Jain N, Jabbour E, Kantarjian H, Champlin R, Konopleva M, Kebriaei P. Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021 07; 56(7):1746-1749. PMID: 33767403.
      Citations:    Fields:    Translation:Humans
    122. Jabbour E, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Kanagal-Shamanna R, Jorgensen J, Khouri IF, Kebriaei P, Jain N, Alvarado Y, Kadia TM, Paul S, Garcia-Manero G, Dabaja BS, Burger JA, DiNardo CD, Daver NA, Montalban-Bravo G, Yilmaz M, Ohanian M, Ferrajoli A, Jacob J, Rostykus M, Garris R, O'Brien S, Kantarjian HM. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2021 06 15; 127(12):2025-2038. PMID: 33740268.
      Citations: 1     Fields:    Translation:HumansCells
    123. Morita K, Jain N, Kantarjian H, Takahashi K, Fang H, Konopleva M, El Hussein S, Wang F, Short NJ, Maiti A, Sasaki K, Garcia-Manero G, Konoplev S, Ravandi F, Khoury JD, Jabbour E. Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine. Am J Hematol. 2021 05 01; 96(5):589-598. PMID: 33639000.
      Citations: 7     Fields:    Translation:Humans
    124. Fiskus W, Mill CP, Perera D, Birdwell C, Deng Q, Yang H, Lara BH, Jain N, Burger J, Ferrajoli A, Davis JA, Saenz DT, Jin W, Coarfa C, Crews CM, Green MR, Khoury JD, Bhalla KN. BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma. Leukemia. 2021 09; 35(9):2621-2634. PMID: 33654205; PMCID: PMC8410602.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    125. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Veletic I, Ferrajoli A, Bose P, Thompson P, Jain N, Verstovsek S, Wierda W, Keating MJ, Estrov Z. STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells. Oncotarget. 2021 Mar 02; 12(5):401-411. PMID: 33747356; PMCID: PMC7939524.
      Citations: 3     Fields:    
    126. Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. 2021 03 01; 106(3):894-898. PMID: 32499238; PMCID: PMC7927994.
      Citations: 13     Fields:    Translation:Humans
    127. Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J. 2021 02 01; 11(2):25. PMID: 33563904; PMCID: PMC7873265.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    128. Gehring T, Lupo C, Kordts A, Solar Nikolic D, Jain N, Rydberg T, Pirandola S, Andersen UL, Pedersen TB. Homodyne-based quantum random number generator at 2.9 Gbps secure against quantum side-information. Nat Commun. 2021 Jan 27; 12(1):605. PMID: 33504789; PMCID: PMC7840728.
      Citations:    Fields:    
    129. Abou Dalle I, Kantarjian HM, Ravandi F, Daver N, Wang X, Jabbour E, Estrov Z, DiNardo CD, Pemmaraju N, Ferrajoli A, Jain N, Wang SA, Jammal N, Borthakur G, Naqvi K, Pelletier S, Pierce S, Andreeff M, Garcia-Manero G, Cortes JE, Kadia TM. Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer. 2021 06 01; 127(11):1894-1900. PMID: 33449377.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    130. Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol. 2021 03 01; 96(3):282-291. PMID: 33264443; PMCID: PMC8128145.
      Citations: 15     Fields:    Translation:Humans
    131. Koller PB, Zhang H, Kantarjian H, Jabbour E, Pierce S, Gocho Y, Roberts KG, Yang W, Mullighan CG, Yang J, Konopleva M, Jain N. GATA3 rs3824662A allele in B-cell acute lymphoblastic leukemia in adults, adolescents and young adults: association with CRLF2 rearrangement and poor prognosis. Am J Hematol. 2021 03 01; 96(3):E71-E74. PMID: 33275800.
      Citations: 2     Fields:    Translation:Humans
    132. Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar OC, Lucchini G, Pinner D, Jain N, Kantarjian H, Maus MV, Frigault MJ, Mohty M, Gianella-Borradori A, Binlich F, Balandraud S, Vitry F, Thomas E, Philippe A, Fouliard S, Dupouy S, Marchiq I, Almena-Carrasco M, Ferry N, Arnould S, Konto C, Veys P, Qasim W, UCART19 Group, Boissel N, Baruchel A. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet. 2020 12 12; 396(10266):1885-1894. PMID: 33308471.
      Citations: 50     Fields:    Translation:HumansCTClinical Trials
    133. Sivina M, Xiao L, Kim E, Vaca A, Chen SS, Keating MJ, Ferrajoli A, Estrov Z, Jain N, Wierda WG, Huang X, Chiorazzi N, Burger JA. CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia. Leukemia. 2021 06; 35(6):1610-1620. PMID: 33087831.
      Citations: 4     Fields:    Translation:Humans
    134. Lyapichev KA, Sukswai N, Angelova E, Kersh MJ, Pierce S, Konopleva M, Jain N, Jabbour EJ, Jorgensen JL, Wang SA, Medeiros LJ, Khoury JD, Konoplev S. CD123 Expression in Philadelphia Chromosome-like B Acute Lymphoblastic Leukemia/Lymphoma. Clin Lymphoma Myeloma Leuk. 2021 04; 21(4):e317-e320. PMID: 33129747.
      Citations: 2     Fields:    Translation:HumansCells
    135. Gupta SK, Jain N, Tang G, Futreal A, Wang SA, Khoury JD, Yang RK, Fang H, Patel KP, Luthra R, Routbort M, Barkoh BA, Chen W, Mao X, Zhang J, Medeiros LJ, Bueso-Ramos CE, Loghavi S. A Cryptic BCR-PDGFRB Fusion Resulting in a Chronic Myeloid Neoplasm With Monocytosis and Eosinophilia: A Novel Finding With Treatment Implications. J Natl Compr Canc Netw. 2020 10; 18(10):1300-1304. PMID: 33022638.
      Citations: 1     Fields:    Translation:Humans
    136. Hampel PJ, Cherng HJ, Call TG, Ding W, Khanlari M, McPhail ED, Miranda RN, Lin P, Tawbi HA, Ferrajoli A, Wierda WG, Jain N, Parikh SA. Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib. Blood Adv. 2020 09 22; 4(18):4508-4511. PMID: 32946567; PMCID: PMC7509865.
      Citations: 2     Fields:    Translation:Humans
    137. Yilmaz M, Kantarjian HM, Toruner G, Yin CC, Kanagal-Shamanna R, Cortes JE, Issa G, Short NJ, Khoury JD, Garcia-Manero G, Ravandi F, Kadia T, Konopleva M, Wierda WG, Jain N, Estrov Z, Sasaki K, Pierce S, O'Brien SM, Jabbour EJ. Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. Leuk Lymphoma. 2021 01; 62(1):224-228. PMID: 32955970.
      Citations:    Fields:    Translation:HumansCells
    138. Cherng HJ, Jain N, Thakral B, Muzzafar T, Miranda RN, Tan D, Rashid A, Kalhor N, Hahn AW, Byers LA, Parseghian CM, Ferrajoli A, Pemmaraju N. Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia. Leuk Res. 2020 11; 98:106445. PMID: 32937250; PMCID: PMC9153129.
      Citations:    Fields:    Translation:Humans
    139. DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020 Oct; 7(10):e724-e736. PMID: 32896301; PMCID: PMC7549397.
      Citations: 62     Fields:    Translation:HumansCTClinical Trials
    140. Gandhi D, Jain N, Khanna K, Li S, Patel L, Gupta N. Current role of imaging in COVID-19 infection with recent recommendations of point of care ultrasound in the contagion: a narrative review. Ann Transl Med. 2020 Sep; 8(17):1094. PMID: 33145313; PMCID: PMC7576001.
      Citations: 10     
    141. Samra B, Alotaibi AS, Short NJ, Khoury JD, Ravandi F, Garris R, Jain N, Konopleva M, Kantarjian H, Jabbour E. Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Am J Hematol. 2020 09; 95(9):E245-E247. PMID: 32501545.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    142. Paul S, Jammal N, Akhave N, Aung PP, Loghavi S, Jain N, Garcia-Manero G, Borthakur G, Verstovsek S, Jabbour E, Adachi J, Masarova L, Daver N, Ravandi F, Pemmaraju N. Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia. Br J Haematol. 2020 10; 191(1):e10-e13. PMID: 32686139.
      Citations: 1     Fields:    Translation:Humans
    143. Pandey RK, DiPippo A, Kadia T, Pemmaraju N, Workeneh BT, Jabbour E, Ravandi F, Jain N. Nelarabine-related rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2020 11; 61(11):2775-2777. PMID: 32654562.
      Citations: 2     Fields:    Translation:HumansCells
    144. Alotaibi AS, Abdulrazzaq M, Patel KP, Ravandi F, Konoplev S, Bueso-Ramos C, Yin CC, Muzzafar T, Tang G, Futreal A, Jain N, Konopleva MY, Pemmaraju N. Acute promyelocytic leukemia (APL) with an IRF2BP2-RARA fusion transcript: an aggressive APL variant. Leuk Lymphoma. 2020 12; 61(12):3018-3020. PMID: 32657180.
      Citations: 2     Fields:    Translation:Humans
    145. Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, Gu Z, Wang F, Huang X, Sasaki K, Short NJ, Jain N, Ravandi F, Daver NG, Kadia TM, Alvarado Y, DiNardo CD, Issa GC, Pemmaraju N, Garcia-Manero G, Verstovsek S, Wang S, Khoury JD, Jorgensen J, Champlin R, Khouri I, Kebriaei P, Schroeder H, Khouri M, Mullighan CG, Takahashi K, O'Brien SM, Kantarjian H. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Jul; 7(7):e523-e533. PMID: 32589978.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    146. John TM, Malek AE, Mulanovich VE, Adachi JA, Raad II, Hamilton AR, Shpall EJ, Rezvani K, Aitken SL, Jain N, Klein K, Martinez F, Jacob CN, Cherian SV, Manzano JM, Muthu M, Wegner R. Migratory Pulmonary Infiltrates in a Patient With COVID-19 Infection and the Role of Corticosteroids. Mayo Clin Proc. 2020 09; 95(9):2038-2040. PMID: 32861345; PMCID: PMC7311909.
      Citations: 2     Fields:    Translation:HumansCellsPHPublic Health
    147. Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia. 2020 11; 34(11):2914-2924. PMID: 32546726.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    148. Frei M, Aitken SL, Jain N, Thompson P, Wierda W, Kontoyiannis DP, DiPippo AJ. Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib. Leuk Lymphoma. 2020 10; 61(10):2488-2491. PMID: 32530347.
      Citations: 8     Fields:    Translation:Humans
    149. Paul S, Rausch CR, Jain N, Kadia T, Ravandi F, DiNardo CD, Welch MA, Dabaja BS, Daver N, Garcia-Manero G, Wierda W, Pemmaraju N, Montalban Bravo G, Thompson P, Verstovsek S, Konopleva M, Kantarjian H, Jabbour E. Treating Leukemia in the Time of COVID-19. Acta Haematol. 2021; 144(2):132-145. PMID: 32392559; PMCID: PMC7270066.
      Citations: 18     Fields:    Translation:HumansCellsPHPublic Health
    150. Sasaki K, Kantarjian H, Wierda W, Ravandi-Kashani F, Jorgensen J, Wang SA, Khoury J, Daver N, Burger J, Di Nardo CD, Jain N, Short NJ, Estrov Md Z, Konopleva Md PhD M, Ohanian DO M, Garcia-Manero G, Kadia T, Alvarado-Valero Y, Yilmaz M, Pierce S, Garris R, Ingram A, Cortes J, O'Brien S, Jabbour E. Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol. 2020 07; 95(7):734-739. PMID: 32170867.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    151. Jain NB, Borg-Stein J, Miranda-Comas G, Micheo W, Visco C, Fredericson M. Recommendations for Enhancing Sports Medicine Fellowship Training. Am J Phys Med Rehabil. 2020 04; 99(4):348-352. PMID: 31738281.
      Citations: 1     Fields:    Translation:Humans
    152. Yanik EL, Colditz GA, Wright RW, Saccone NL, Evanoff BA, Jain NB, Dale AM, Keener JD. Risk factors for surgery due to rotator cuff disease in a population-based cohort. Bone Joint J. 2020 Mar; 102-B(3):352-359. PMID: 32114822; PMCID: PMC7552877.
      Citations: 2     Fields:    Translation:HumansPHPublic Health
    153. Cahill KE, Karimi YH, Karrison TG, Jain N, Green M, Weiner H, Fulton N, Kadri S, Godley LA, Artz AS, Liu H, Thirman MJ, Le Beau MM, McNerney ME, Segal J, Larson RA, Stock W, Odenike O. A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. Blood Adv. 2020 02 25; 4(4):599-606. PMID: 32074275; PMCID: PMC7042987.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    154. Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. 2020 09; 34(9):2489-2492. PMID: 32099037.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    155. Strati P, Schlette EJ, Solis Soto LM, Duenas DE, Sivina M, Kim E, Keating MJ, Wierda WG, Ferrajoli A, Kantarjian H, Estrov Z, Jain N, Thompson PA, Wistuba II, Burger JA. Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors. Blood. 2020 02 13; 135(7):510-513. PMID: 31895947; PMCID: PMC7019190.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    156. Jain N, Stock W, Zeidan A, Atallah E, McCloskey J, Heffner L, Tomlinson B, Bhatnagar B, Feingold J, Ungar D, Chao G, Zhang X, Qin Y, Havenith K, Kantarjian H, Wieduwilt MJ. Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia. Blood Adv. 2020 02 11; 4(3):449-457. PMID: 32012214; PMCID: PMC7013258.
      Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
    157. Kim E, Ten Hacken E, Sivina M, Clarke A, Thompson PA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG, Bhalla KN, Burger JA. The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. Leukemia. 2020 06; 34(6):1588-1598. PMID: 31862959; PMCID: PMC7272263.
      Citations: 5     Fields:    Translation:HumansCells
    158. Karjalainen TV, Jain NB, Heikkinen J, Johnston RV, Page CM, Buchbinder R. Surgery for rotator cuff tears. Cochrane Database Syst Rev. 2019 12 09; 12:CD013502. PMID: 31813166; PMCID: PMC6900168.
      Citations: 16     Fields:    Translation:Humans
    159. Thompson PA, Srivastava J, Peterson C, Strati P, Jorgensen JL, Hether T, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Wierda WG. Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood. 2019 11 28; 134(22):1951-1959. PMID: 31537528; PMCID: PMC6887113.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    160. Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour E. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol. 2020 02; 95(2):144-150. PMID: 31682008.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    161. Jain N, O'Brien S. The Shifting Paradigm in Chronic Lymphocytic Leukemia: Is Chemotherapy Still Relevant? Cancer J. 2019 Nov/Dec; 25(6):374-377. PMID: 31764117.
      Citations: 3     Fields:    Translation:Humans
    162. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Uziel O, Keating MJ, Estrov Z. STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage. J Immunol. 2019 12 01; 203(11):3078-3085. PMID: 31645416; PMCID: PMC6864283.
      Citations: 9     Fields:    Translation:HumansCells
    163. Abou Dalle I, Kantarjian HM, Short NJ, Konopleva M, Jain N, Garcia-Manero G, Garris R, Qiao W, Cortes JE, O'Brien S, Kebriaei P, Kadia T, Jabbour E, Ravandi F. Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. Am J Hematol. 2019 12; 94(12):1388-1395. PMID: 31595534.
      Citations: 7     Fields:    Translation:HumansCells
    164. Alfayez M, Thakral B, Jain P, Ravandi F, Ferrajoli A, Jain N, Pemmaraju N, Wierda W, Kadia T. First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL). Leuk Lymphoma. 2020 02; 61(2):445-449. PMID: 31566032.
      Citations: 5     Fields:    Translation:HumansCells
    165. Richard-Carpentier G, Jabbour E, Short NJ, Rausch CR, Savoy JM, Bose P, Yilmaz M, Jain N, Borthakur G, Ohanian M, Alvarado Y, Rytting M, Kebriaei P, Konopleva M, Kantarjian H, Ravandi F. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2020 04; 20(4):212-218. PMID: 32035785.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    166. Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Long-term follow-up of lower dose dasatinib (50?mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2020 01 01; 126(1):67-75. PMID: 31553487; PMCID: PMC8529949.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    167. Jain NB, Ayers GD, Fan R, Kuhn JE, Warner JJP, Baumgarten KM, Matzkin E, Higgins LD. Comparative Effectiveness of Operative Versus Nonoperative Treatment for Rotator Cuff Tears: A Propensity Score Analysis From the ROW Cohort. Am J Sports Med. 2019 11; 47(13):3065-3072. PMID: 31518155; PMCID: PMC7325686.
      Citations: 2     Fields:    Translation:Humans
    168. Dabija DI, Guan H, Neviaser A, Jain NB. Readmissions, revisions, and mortality after treatment for proximal humeral fractures in three large states. BMC Musculoskelet Disord. 2019 Sep 11; 20(1):419. PMID: 31506075; PMCID: PMC6737688.
      Citations: 2     Fields:    Translation:Humans
    169. Jain N, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. Reply. N Engl J Med. 2019 08 22; 381(8):789. PMID: 31433937.
      Citations: 2     Fields:    Translation:Humans
    170. Kazma J, Johnson C, Jain N, Gali VL, Young KH, Jazaeri AA. B-cell acute lymphoblastic leukemia/lymphoma in relapse presenting as a cervical mass: A case report and review of literature. Gynecol Oncol Rep. 2019 Aug; 29:94-97. PMID: 31467959; PMCID: PMC6710557.
      Citations:    
    171. Dabija DI, Pennings JS, Archer KR, Ayers GD, Higgins LD, Kuhn JE, Baumgarten KM, Matzkin E, Jain NB. Which Is the Best Outcome Measure for Rotator Cuff Tears? Clin Orthop Relat Res. 2019 Aug; 477(8):1869-1878. PMID: 31335605; PMCID: PMC7000030.
      Citations: 3     Fields:    Translation:Humans
    172. Strati P, Wang F, Tambaro FP, Thompson PA, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Futreal A, Takahashi K, Wierda WG. The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. Br J Haematol. 2019 10; 187(1):e1-e4. PMID: 31344256.
      Citations: 2     Fields:    Translation:Humans
    173. Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating M, Wierda WG. Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol. 2019 11; 187(3):307-318. PMID: 31243771.
      Citations: 7     Fields:    Translation:Humans
    174. Jain N. Optimizing drug dosing for the treatment of chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2019 Jun; 17(6):330-331. PMID: 31437134.
      Citations:    Fields:    Translation:Humans
    175. Chamoun K, Kantarjian HM, Wang X, Naqvi K, Aung F, Garcia-Manero G, Borthakur G, Jabbour E, Kadia T, Daver N, DiNardo CD, Jain N, Konopleva M, Cortes J, Ravandi F, Yilmaz M. Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. Cancer. 2019 09 15; 125(18):3219-3224. PMID: 31150121.
      Citations: 5     Fields:    Translation:Humans
    176. Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019 05 30; 380(22):2095-2103. PMID: 31141631.
      Citations: 139     Fields:    Translation:HumansCTClinical Trials
    177. Khogeer H, Rahman H, Jain N, Angelova EA, Yang H, Quesada A, Ok CY, Sui D, Wei P, Al Fattani A, Pierce S, Loghavi S, Lamb A, Hu P, Thakral B, Kanagal-Shamanna R, Jorgensen JL, Jabbour EJ, Kantarjian HM, Medeiros LJ, Khoury JD. Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy. Br J Haematol. 2019 08; 186(4):538-548. PMID: 31115909.
      Citations: 9     Fields:    Translation:HumansCells
    178. Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli A. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Adv. 2019 05 14; 3(9):1533-1539. PMID: 31076409; PMCID: PMC6517659.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    179. Kumar A, Agarwal A, Sharma A, Agarwal D, Jain N, Gupta P. Myxoedema coma following commencement of anti-TNF therapy and tuberculosis prophylaxis in a patient with RA and latent tuberculosis infection. Postgrad Med J. 2019 May; 95(1123):281. PMID: 31085622.
      Citations:    Fields:    Translation:Humans
    180. Brown PA, Wieduwilt M, Logan A, DeAngelo DJ, Wang ES, Fathi A, Cassaday RD, Litzow M, Advani A, Aoun P, Bhatnagar B, Boyer MW, Bryan T, Burke PW, Coccia PF, Coutre SE, Jain N, Kirby S, Liu A, Massaro S, Mattison RJ, Oluwole O, Papadantonakis N, Park J, Rubnitz JE, Uy GL, Gregory KM, Ogba N, Shah B. Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019. J Natl Compr Canc Netw. 2019 05 01; 17(5):414-423. PMID: 31085755.
      Citations: 18     Fields:    Translation:Humans
    181. Tallis E, Loghavi S, Jorgensen JL, Wang S, Khoury JD, Bueso-Ramos CB, Jain N, Borthakur G, Pemmaraju N. Patient with mixed-phenotype acute leukemia with CBFB rearrangement. Leuk Lymphoma. 2019 11; 60(11):2829-2831. PMID: 31012358.
      Citations:    Fields:    Translation:Humans
    182. Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Cortes J, Issa GC, Jacob J, Kwari M, Thompson P, Garris R, Pemmaraju N, Yilmaz M, O'Brien SM, Kantarjian HM. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2019 08 01; 125(15):2579-2586. PMID: 30985931; PMCID: PMC6625850.
      Citations: 20     Fields:    Translation:Humans
    183. Hu B, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WG. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol. 2019 06; 185(5):852-864. PMID: 30924136.
      Citations: 5     Fields:    Translation:Humans
    184. Ragon BK, Odenike O, Baer MR, Stock W, Borthakur G, Patel K, Han L, Chen H, Ma H, Joseph L, Zhao Y, Baggerly K, Konopleva M, Jain N. Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study. Clin Lymphoma Myeloma Leuk. 2019 07; 19(7):431-440.e13. PMID: 31056348; PMCID: PMC6626580.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    185. Gale RP, Mahmood S, Devonport H, Patel PJ, Ross AH, Walters G, Downey L, El-Sherbiny S, Freeman M, Berry S, Jain N. Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service. Eye (Lond). 2019 03; 33(Suppl 1):1-21. PMID: 30926932; PMCID: PMC6474281.
      Citations: 16     Fields:    Translation:Humans
    186. Ramiro S, Page MJ, Whittle SL, Huang H, Verhagen AP, Beaton DE, Richards P, Voshaar M, Shea B, van der Windt DA, Kopkow C, Lenza M, Jain NB, Richards B, Hill C, Gill TK, Koes B, Foster NE, Conaghan PG, Smith T, Malliaras P, Roe Y, Gagnier JJ, Buchbinder R. The OMERACT Core Domain Set for Clinical Trials of Shoulder Disorders. J Rheumatol. 2019 08; 46(8):969-975. PMID: 30709947.
      Citations: 6     Fields:    Translation:Humans
    187. Kantarjian HM, Jabbour EJ, Garcia-Manero G, Kadia TM, DiNardo CD, Daver NG, Borthakur G, Jain N, Waukau JB, Kwari MI, Ravandi F, Anderson BD, Iizuka K, Jin C, Zhang C, Plunkett WK. Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. Cancer. 2019 05 15; 125(10):1665-1673. PMID: 30668890.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    188. Karjalainen TV, Jain NB, Page CM, Johnston RV, Salamh P, Kavaja L, Ardern CL, Agarwal A, Vandvik PO, Buchbinder R, L?hdeoja TA. Subacromial decompression surgery for rotator cuff disease. Cochrane Database Syst Rev. 2019 01 17; 1:CD005619. PMID: 30707445; PMCID: PMC6357907.
      Citations: 26     Fields:    Translation:Humans
    189. Chamoun K, Kantarjian H, Atallah R, Gonzalez GN, Issa GC, Rios MB, Garcia-Manero G, Borthakur G, Ravandi F, Jain N, Daver N, Konopleva M, DiNardo CD, Kadia T, Pemmaraju N, Jabbour E, Cortes J. Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. J Hematol Oncol. 2019 01 03; 12(1):1. PMID: 30606227; PMCID: PMC6318861.
      Citations: 9     Fields:    Translation:Humans
    190. Dickinson RN, Ayers GD, Archer KR, Fan R, Page C, Higgins LD, Kuhn JE, Baumgarten KM, Matzkin E, Jain NB. Physical therapy versus natural history in outcomes of rotator cuff tears: the Rotator Cuff Outcomes Workgroup (ROW) cohort study. J Shoulder Elbow Surg. 2019 May; 28(5):833-838. PMID: 30553798; PMCID: PMC9186215.
      Citations: 6     Fields:    Translation:Humans
    191. Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol. 2019 Jan; 6(1):e29-e37. PMID: 30545576; PMCID: PMC6563344.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    192. Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Jorgensen J, Li J, Cheng M, Clow F, Ohanian M, Andreeff M, Mathew T, Thompson P, Kantarjian H, O'Brien S, Wierda WG, Ferrajoli A, Keating MJ. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019 03 07; 133(10):1011-1019. PMID: 30530801; PMCID: PMC6405333.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    193. Benton CB, Chien KS, Tefferi A, Rodriguez J, Ravandi F, Daver N, Jabbour E, Jain N, Alvarado Y, Kwari M, Pierce S, Maiti A, Hornbaker M, Santos MA, Martinez S, Siguero M, Zblewski D, Al-Kali A, Hogan WJ, Kantarjian H, Pardanani A, Garcia-Manero G. Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome. Hematol Oncol. 2019 Feb; 37(1):96-102. PMID: 30153704; PMCID: PMC6386594.
      Citations: 5     Fields:    Translation:HumansCells
    194. Kanagal-Shamanna R, Jain P, Patel KP, Routbort M, Bueso-Ramos C, Alhalouli T, Khoury JD, Luthra R, Ferrajoli A, Keating M, Jain N, Burger J, Estrov Z, Wierda W, Kantarjian HM, Medeiros LJ. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer. 2019 02 15; 125(4):559-574. PMID: 30508305.
      Citations: 26     Fields:    Translation:Humans
    195. Jabbour E, Short NJ, Ravandi F, Huang X, Daver N, DiNardo CD, Konopleva M, Pemmaraju N, Wierda W, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Khoury JD, Jorgensen J, Jain N, Alvarez J, O'Brien S, Kantarjian H. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol. 2018 Dec; 5(12):e618-e627. PMID: 30501869; PMCID: PMC10020885.
      Citations: 50     Fields:    Translation:HumansCellsCTClinical Trials
    196. Jain N. Selecting Frontline Therapy for CLL in 2018. Hematology Am Soc Hematol Educ Program. 2018 11 30; 2018(1):242-247. PMID: 30504317; PMCID: PMC6245995.
      Citations: 8     Fields:    Translation:HumansCells
    197. Boddu P, Thakral B, Alhuraiji A, Pemmaraju N, Kadia T, Ohanian M, Ravandi F, Jabbour E, Wierda W, Khoury JD, Jain N. Distinguishing thymoma from T-lymphoblastic leukaemia/lymphoma: a case-based evaluation. J Clin Pathol. 2019 Mar; 72(3):251-257. PMID: 30467242.
      Citations: 2     Fields:    Translation:Humans
    198. Paul S, Jain N, Ferrajoli A, O'Brien S, Burger J, Keating M, Wierda W. A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia. Br J Haematol. 2019 05; 185(3):606-608. PMID: 30406944.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    199. O'Brien S, Patel M, Kahl BS, Horwitz SM, Foss FM, Porcu P, Jones J, Burger J, Jain N, Allen K, Faia K, Douglas M, Stern HM, Sweeney J, Kelly P, Kelly V, Flinn I. Duvelisib, an oral dual PI3K-d,? inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. Am J Hematol. 2018 11; 93(11):1318-1326. PMID: 30094870; PMCID: PMC8260004.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    200. Jabbour E, Sasaki K, Ravandi F, Huang X, Short NJ, Khouri M, Kebriaei P, Burger J, Khoury J, Jorgensen J, Jain N, Konopleva M, Garcia-Manero G, Kadia T, Cortes J, Jacob J, Montalbano K, Garris R, O'Brien S, Kantarjian HM. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer. 2018 10 15; 124(20):4044-4055. PMID: 30307611; PMCID: PMC6515924.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    201. Chen LS, Bose P, Cruz ND, Jiang Y, Wu Q, Thompson PA, Feng S, Kroll MH, Qiao W, Huang X, Jain N, Wierda WG, Keating MJ, Gandhi V. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood. 2018 11 22; 132(21):2249-2259. PMID: 30254130; PMCID: PMC6251009.
      Citations: 29     Fields:    Translation:HumansCellsCTClinical Trials
    202. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells. Oncotarget. 2018 Sep 14; 9(72):33710-33718. PMID: 30263097; PMCID: PMC6154750.
      Citations: 4     Fields:    
    203. Ok CY, Medeiros LJ, Thakral B, Tang G, Jain N, Jabbour E, Pierce SA, Konoplev S. High-grade B-cell lymphomas with TdT expression: a diagnostic and classification dilemma. Mod Pathol. 2019 01; 32(1):48-58. PMID: 30181564.
      Citations: 9     Fields:    Translation:Humans
    204. Takahashi K, Wang F, Morita K, Yan Y, Hu P, Zhao P, Zhar AA, Wu CJ, Gumbs C, Little L, Tippen S, Thornton R, Coyle M, Mendoza M, Thompson E, Zhang J, DiNardo CD, Jain N, Ravandi F, Cortes JE, Garcia-Manero G, Kornblau S, Andreeff M, Jabbour E, Bueso-Ramos C, Takaori-Kondo A, Konopleva M, Patel K, Kantarjian H, Futreal PA. Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun. 2018 07 10; 9(1):2670. PMID: 29991687; PMCID: PMC6039465.
      Citations: 26     Fields:    Translation:HumansCells
    205. Jain N, Thompson P, Ferrajoli A, Nabhan C, Mato AR, O'Brien S. Approaches to Chronic Lymphocytic Leukemia Therapy in the Era of New Agents: The Conundrum of Many Options. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:580-591. PMID: 30231393.
      Citations: 5     Fields:    Translation:Humans
    206. Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2018 07 01; 124(13):2740-2747. PMID: 29723397; PMCID: PMC6388399.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    207. Strati P, Jain N, O'Brien S. Chronic Lymphocytic Leukemia: Diagnosis and Treatment. Mayo Clin Proc. 2018 05; 93(5):651-664. PMID: 29728204.
      Citations: 6     Fields:    Translation:Humans
    208. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells. Oncotarget. 2018 Apr 20; 9(30):21268-21280. PMID: 29765537; PMCID: PMC5940394.
      Citations: 20     Fields:    
    209. Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, Daver N, Jabbour E, Wierda WG. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia. 2018 11; 32(11):2388-2398. PMID: 29769624; PMCID: PMC6192870.
      Citations: 12     Fields:    Translation:Humans
    210. Assi R, Kantarjian HM, Kadia TM, Pemmaraju N, Jabbour E, Jain N, Daver N, Estrov Z, Uehara T, Owa T, Cortes JE, Borthakur G. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2018 07 01; 124(13):2758-2765. PMID: 29660836; PMCID: PMC6800041.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    211. Kantarjian HM, DiNardo CD, Nogueras-Gonzalez GM, Kadia TM, Jabbour E, Bueso-Ramos CE, O'Brien SM, Konopleva M, Jain NB, Daver NG, Shpall EJ, Champlin RE, Simkins A, Garcia-Manero G, Keating MJ, Huang X, Cortes JE, Pierce SA, Ravandi F, Freireich EJ. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer. 2018 06 15; 124(12):2534-2540. PMID: 29645075.
      Citations: 8     Fields:    Translation:HumansCells
    212. Coronado RA, Seitz AL, Pelote E, Archer KR, Jain NB. Are Psychosocial Factors Associated With Patient-reported Outcome Measures in Patients With Rotator Cuff Tears? A Systematic Review. Clin Orthop Relat Res. 2018 04; 476(4):810-829. PMID: 29481342; PMCID: PMC6260082.
      Citations: 13     Fields:    Translation:Humans
    213. Boddu P, Jain N. Update on signal inhibitors in chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2018 Apr; 16(4):279-288. PMID: 29742083.
      Citations:    Fields:    Translation:HumansAnimals
    214. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia. Leuk Lymphoma. 2018 11; 59(11):2686-2691. PMID: 29465264; PMCID: PMC6135679.
      Citations: 10     Fields:    Translation:HumansCells
    215. Strati P, Ferrajoli A, Wierda WG, Jain N, Thompson PA, O'Brien SM, Rezvani K, Kantarjian HM, Burger JA, Hinojosa CO, Keating MJ, Estrov Z. Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia. Leukemia. 2018 10; 32(10):2278-2281. PMID: 29479067.
      Citations: 2     Fields:    Translation:Humans
    216. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Locke FL, Lin Y, Jain N, Daver N, Gulbis AM, Adkins S, Rezvani K, Hwu P, Shpall EJ. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol. 2018 04; 15(4):218. PMID: 29434334; PMCID: PMC6716606.
      Citations: 33     Fields:    Translation:Humans
    217. Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, Sasaki K, Rytting M, Jain N, Konopleva M, Garcia-Manero G, Champlin R, Marin D, Kadia T, Cortes J, Estrov Z, Takahashi K, Patel Y, Khouri MR, Jacob J, Garris R, O'Brien S, Kantarjian H. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. JAMA Oncol. 2018 Feb 01; 4(2):230-234. PMID: 28859185; PMCID: PMC5838597.
      Citations: 43     Fields:    Translation:HumansCellsCTClinical Trials
    218. Simkins A, Maiti A, Short NJ, Jain N, Popat U, Patel KP, Oo TH. Acquired amegakaryocytic thrombocytopenia and red cell aplasia in a patient with thymoma progressing to aplastic anemia successfully treated with allogenic stem cell transplantation. Hematol Oncol Stem Cell Ther. 2019 Jun; 12(2):115-118. PMID: 29409729.
      Citations: 4     Fields:    Translation:Humans
    219. Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, Patel KP, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Garcia-Manero G, Kantarjian H, Estrov Z, Do KA, Keating M, Burger JA, Wierda WG, Futreal PA, Ferrajoli A. Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood. 2018 04 19; 131(16):1820-1832. PMID: 29358183; PMCID: PMC5909764.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    220. Zhang Q, Shi C, Han L, Jain N, Roberts KG, Ma H, Cai T, Cavazos A, Tabe Y, Jacamo RO, Mu H, Zhao Y, Wang J, Wu SC, Cao F, Zeng Z, Zhou J, Mi Y, Jabbour EJ, Levine R, Tasian SK, Mullighan CG, Weinstock DM, Fruman DA, Konopleva M. Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia. Oncotarget. 2018 Jan 30; 9(8):8027-8041. PMID: 29487712; PMCID: PMC5814279.
      Citations: 18     Fields:    
    221. Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, Daver N, Pemmaraju N, Khoury JD, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Bortakhur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Garris R, O'Brien S, Jabbour E. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018 02; 19(2):240-248. PMID: 29352703.
      Citations: 58     Fields:    Translation:HumansCTClinical Trials
    222. Sivina M, Kim E, Thenhausen T, Krohn-Grimberghe A, Jain N, Estrov Z, Ferrajoli A, Wierda W, Keating M, Burger JA, Schliffke S, von Wenserski L, Thiele B, Aky?z N, Falker-Gieske C, Statovci D, Oberle A, Bokemeyer C, Binder M. Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy. Oncoimmunology. 2018; 7(4):e1417720. PMID: 29632735; PMCID: PMC5889203.
      Citations: 4     Fields:    
    223. DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, Daver N, Covert W, Marx KR, Mace M, Jabbour E, Cortes J, Garcia-Manero G, Ravandi F, Bhalla KN, Kantarjian H, Konopleva M. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018 03; 93(3):401-407. PMID: 29218851.
      Citations: 126     Fields:    Translation:HumansCells
    224. Jabbour E, Yilmaz M, Khoury JD, Ravandi F, Jain N, Garcia-Manero G, Konopleva M, Short NJ, Thompson PA, Wierda W, Daver N, Cortes J, O'brien S, Kantarjian H, D?ll J, Einsele H, Topp MS. Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. Am J Hematol. 2018 03; 93(3):371-374. PMID: 29178361.
      Citations: 37     Fields:    Translation:HumansCells
    225. Flinn IW, O'Brien S, Kahl B, Patel M, Oki Y, Foss FF, Porcu P, Jones J, Burger JA, Jain N, Kelly VM, Allen K, Douglas M, Sweeney J, Kelly P, Horwitz S. Duvelisib, a novel oral dual inhibitor of PI3K-d,?, is clinically active in advanced hematologic malignancies. Blood. 2018 02 22; 131(8):877-887. PMID: 29191916; PMCID: PMC6033052.
      Citations: 77     Fields:    Translation:HumansCTClinical Trials
    226. Jain P, Kanagal-Shamanna R, Rozovski U, Sarwari N, Tam C, Wierda WG, Thompson PA, Jain N, Luthra R, Quesada A, Sanchez-Petitto G, Ferrajoli A, Burger J, Kantarjian H, Cortes J, O'Brien S, Keating MJ, Estrov Z, Nogueras Gonz?lez GM. The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. Br J Haematol. 2018 01; 180(1):33-40. PMID: 29164608; PMCID: PMC5745295.
      Citations: 11     Fields:    Translation:HumansCells
    227. Abaza Y, M Kantarjian H, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, Borthakur G, D Khoury J, Burger J, Wierda W, O'Brien S, Konopleva M, Ferrajoli A, Kebriaei P, Dabaja B, Kornblau S, Alvarado Y, Daver N, Pemmaraju N, Bose P, Thompson P, Al Azzawi H, Kelly M, Garris R, Jain P, Garcia-Manero G, Cortes J, Ravandi F. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol. 2018 01; 93(1):91-99. PMID: 29047158.
      Citations: 21     Fields:    Translation:Humans
    228. Boddu P, Shah AR, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jain N, Alhuraiji A, Burger J, Kornblau S, Pierce S, Dellasala S, Jabbour E, Kantarjian H, Cortes J. Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma. 2018 06; 59(6):1312-1322. PMID: 28972430; PMCID: PMC6120342.
      Citations: 4     Fields:    Translation:Humans
    229. Boddu P, Garcia-Manero G, Ravandi F, Borthakur G, Jabbour E, DiNardo C, Jain N, Daver N, Pemmaraju N, Anderlini P, Parmar S, Kc D, Akosile M, Pierce SA, Champlin R, Cortes J, Kantarjian H, Kadia T. Clinical outcomes in adult patients with aplastic anemia: A single institution experience. Am J Hematol. 2017 Dec; 92(12):1295-1302. PMID: 28850699; PMCID: PMC5987765.
      Citations: 4     Fields:    Translation:Humans
    230. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018 Jan; 15(1):47-62. PMID: 28925994; PMCID: PMC6733403.
      Citations: 631     Fields:    Translation:Humans
    231. Boddu P, Yin CC, Kanagal-Shamanna R, Tang G, Thakral B, Kadia T, Konopleva M, Jabbour E, Jain N. An Unsuspected Finding of t(9;22): A Rare Case of Philadelphia Chromosome-Positive B-Lymphoblastic Lymphoma. Case Rep Hematol. 2017; 2017:2413587. PMID: 29075538; PMCID: PMC5624137.
      Citations: 5     
    232. Jain N, Lu X, Daver N, Thakral B, Wang SA, Konoplev S, Patel K, Kanagal-Shamanna R, Valentine M, Tang G, Pemmaraju N, Jorgensen J, Kebriaei P, Nunez CA, Wierda W, Jabbour E, Roberts KG, Mullighan CG, Kantarjian H, Konopleva M. Co-occurrence of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients. Haematologica. 2017 12; 102(12):e514-e517. PMID: 28860345; PMCID: PMC5709127.
      Citations: 5     Fields:    Translation:HumansCells
    233. Assi R, Kantarjian H, Short NJ, Daver N, Takahashi K, Garcia-Manero G, DiNardo C, Burger J, Cortes J, Jain N, Wierda W, Chamoun S, Konopleva M, Jabbour E. Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. Clin Lymphoma Myeloma Leuk. 2017 Dec; 17(12):897-901. PMID: 28927784.
      Citations: 45     Fields:    Translation:Humans
    234. Boddu P, Schlette E, Thakral B, Tang G, Pemmaraju N, Kadia T, Ferrajoli A, Ravandi F, Wierda W, Jain N. Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia-A case report. Hematol Oncol Stem Cell Ther. 2019 Sep; 12(3):161-165. PMID: 28830803.
      Citations:    Fields:    Translation:Humans
    235. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Activation of the B-cell receptor successively activates NF-?B and STAT3 in chronic lymphocytic leukemia cells. Int J Cancer. 2017 11 15; 141(10):2076-2081. PMID: 28722170; PMCID: PMC5749978.
      Citations: 10     Fields:    Translation:HumansCells
    236. Jain P, Kantarjian H, Jain N, Short NJ, Yin CC, Kanagal-Shamanna R, Khoury J, Konopleva M, Sasaki K, Kadia TM, Garris R, Pierce S, Estrov Z, Wierda W, Cortes J, O'Brien S, Ravandi F, Jabbour E. Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens. Am J Hematol. 2017 10; 92(10):E595-E597. PMID: 28646517; PMCID: PMC5689471.
      Citations: 2     Fields:    Translation:Humans
    237. Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2018 04; 59(4):813-820. PMID: 28718728; PMCID: PMC5773400.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    238. Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Kantarjian H. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer. 2017 Nov 15; 123(22):4430-4439. PMID: 28708931; PMCID: PMC5739034.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    239. Wells J, Jain N, Konopleva M. Philadelphia chromosome-like acute lymphoblastic leukemia: progress in a new cancer subtype. Clin Adv Hematol Oncol. 2017 Jul; 15(7):554-561. PMID: 28749919.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    240. Kanagal-Shamanna R, Jain P, Takahashi K, Short NJ, Tang G, Issa GC, Ravandi F, Garcia-Manero G, Yin CC, Luthra R, Patel KP, Khoury JD, Montalban-Bravo G, Sasaki K, Kadia TM, Borthakur G, Konopleva M, Jain N, Garris R, Pierce S, Wierda W, Estrov Z, Cortes J, O'Brien S, Kantarjian HM, Jabbour E. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. Cancer. 2017 Oct 01; 123(19):3717-3724. PMID: 28608976; PMCID: PMC5689475.
      Citations: 7     Fields:    Translation:Humans
    241. Kantarjian HM, Schuster MW, Jain N, Advani A, Jabbour E, Gamelin E, Rasmussen E, Juan G, Anderson A, Chow VF, Friberg G, Vogl FD, Sekeres MA. A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia. Am J Hematol. 2017 Jul; 92(7):660-667. PMID: 28370201; PMCID: PMC5925751.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    242. Vangapandu HV, Jain N, Gandhi V. Duvelisib: a phosphoinositide-3 kinase d/? inhibitor for chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2017 May; 26(5):625-632. PMID: 28388280; PMCID: PMC5584596.
      Citations: 21     Fields:    Translation:HumansAnimals
    243. Boddu PC, Kantarjian HM, Ravandi F, Garcia-Manero G, Verstovsek S, Jabbour EJ, Takahashi K, Bhalla K, Konopleva M, DiNardo CD, Ohanian M, Pemmaraju N, Jain N, Pierce S, Wierda WG, Cortes JE, Kadia TM. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer. 2017 Aug 15; 123(16):3050-3060. PMID: 28387922; PMCID: PMC5544569.
      Citations: 15     Fields:    Translation:Humans
    244. Konoplev S, Lu X, Konopleva M, Jain N, Ouyang J, Goswami M, Roberts KG, Valentine M, Mullighan CG, Bueso-Ramos C, Zweidler-McKay PA, Jorgensen JL, Wang SA. CRLF2-Positive B-Cell Acute Lymphoblastic Leukemia in Adult Patients: A Single-Institution Experience. Am J Clin Pathol. 2017 04 01; 147(4):357-363. PMID: 28340183.
      Citations: 10     Fields:    Translation:HumansCells
    245. Jain N, Balakrishnan K, Ferrajoli A, O'Brien SM, Burger JA, Kadia TM, Cortes JE, Ayres ML, Tambaro FP, Keating MJ, Gandhi V, Wierda WG. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. Oncotarget. 2017 Mar 28; 8(13):22104-22112. PMID: 27655665; PMCID: PMC5400650.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    246. Chen Q, Jain N, Flowers CR, Chhatwal J. Reply to C. Nabhan et al. J Clin Oncol. 2017 06 01; 35(16):1864-1865. PMID: 28549223.
      Citations: 1     Fields:    Translation:Humans
    247. Jain NB, Luz J, Higgins LD, Dong Y, Warner JJ, Matzkin E, Katz JN. The Diagnostic Accuracy of Special Tests for Rotator Cuff Tear: The ROW Cohort Study. Am J Phys Med Rehabil. 2017 Mar; 96(3):176-183. PMID: 27386812; PMCID: PMC5218987.
      Citations: 19     Fields:    Translation:Humans
    248. Jain P, Thompson PA, Keating M, Estrov Z, Ferrajoli A, Jain N, Kantarjian H, Burger JA, O'Brien S, Wierda WG. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer. 2017 Jun 15; 123(12):2268-2273. PMID: 28171709; PMCID: PMC5980235.
      Citations: 42     Fields:    Translation:Humans
    249. Pemmaraju N, Jain P, Medeiros LJ, Jorgenson JL, Jain N, Willis J, Kontoyiannis DP, Estrov Z, Wierda WG. PET-positive lymphadenopathy in CLL-Not always Richter transformation. Am J Hematol. 2017 04; 92(4):405-406. PMID: 27677095; PMCID: PMC5352509.
      Citations: 4     Fields:    Translation:Humans
    250. Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Ko H, Cameron Yin C, Garcia-Manero G, Cortes JE, Garris R, O'Brien SM, Patel K, Khouri M, Thomas D, Jain N, Kadia TM, Daver NG, Benton CB, Issa GC, Konopleva M, Jabbour E. Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol. 2017 Mar; 92(3):238-243. PMID: 28006851; PMCID: PMC5495018.
      Citations: 12     Fields:    Translation:HumansCells
    251. Pemmaraju N, Kantarjian H, Jorgensen JL, Jabbour E, Jain N, Thomas D, O'Brien S, Wang X, Huang X, Wang SA, Konopleva M, Konoplev S, Kadia T, Garris R, Pierce S, Garcia-Manero G, Cortes J, Ravandi F. Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. Am J Hematol. 2017 Mar; 92(3):279-285. PMID: 28052371; PMCID: PMC5851443.
      Citations: 11     Fields:    Translation:Humans
    252. Pinnix CC, Chi L, Jabbour EJ, Milgrom SA, Smith GL, Daver N, Garg N, Cykowski MD, Fuller G, Cachia D, Kamiya-Matsuoka C, Woodman K, Dinardo C, Jain N, Kadia TM, Pemmaraju N, Ohanian M, Konopleva M, Kantarjian HM, Dabaja BS. Dorsal column myelopathy after intrathecal chemotherapy for leukemia. Am J Hematol. 2017 Feb; 92(2):155-160. PMID: 27874212; PMCID: PMC5338569.
      Citations: 1     Fields:    Translation:Humans
    253. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, O'Brien S, Bose P, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex. Mol Cancer Res. 2017 05; 15(5):610-618. PMID: 28130399; PMCID: PMC5415425.
      Citations: 12     Fields:    Translation:HumansCells
    254. Buchbinder R, Page MJ, Huang H, Verhagen AP, Beaton D, Kopkow C, Lenza M, Jain NB, Richards B, Richards P, Voshaar M, van der Windt D, Gagnier JJ, Shoulder Core Outcome Set Special Interest Group. A Preliminary Core Domain Set for Clinical Trials of Shoulder Disorders: A Report from the OMERACT 2016 Shoulder Core Outcome Set Special Interest Group. J Rheumatol. 2017 Dec; 44(12):1880-1883. PMID: 28089972.
      Citations: 13     Fields:    Translation:Humans
    255. Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, Harris D, Li P, Liu Z, Veletic I, Rozovski U, Jain N, Thompson P, Bose P, DiNardo C, Ferrajoli A, O'Brien S, Burger J, Wierda W, Verstovsek S, Kantarjian H, Estrov Z. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol. 2017 Feb; 4(2):e67-e74. PMID: 28089238; PMCID: PMC5356368.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    256. Yin Q, Sivina M, Robins H, Yusko E, Vignali M, O'Brien S, Keating MJ, Ferrajoli A, Estrov Z, Jain N, Wierda WG, Burger JA. Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia. J Immunol. 2017 02 15; 198(4):1740-1747. PMID: 28077600; PMCID: PMC5296363.
      Citations: 53     Fields:    Translation:HumansCells
    257. Khan M, Paul S, Farooq S, Oo TH, Ramshesh P, Jain N. Rasburicase-Induced Methemoglobinemia in a Patient with Glucose-6- Phosphate Dehydrogenase Deficiency. Curr Drug Saf. 2017; 12(1):13-18. PMID: 28078984.
      Citations: 4     Fields:    Translation:Humans
    258. Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017 03 09; 129(10):1275-1283. PMID: 28003274; PMCID: PMC5413297.
      Citations: 73     Fields:    Translation:HumansCTClinical Trials
    259. Jain N, Roberts KG, Jabbour E, Patel K, Eterovic AK, Chen K, Zweidler-McKay P, Lu X, Fawcett G, Wang SA, Konoplev S, Harvey RC, Chen IM, Payne-Turner D, Valentine M, Thomas D, Garcia-Manero G, Ravandi F, Cortes J, Kornblau S, O'Brien S, Pierce S, Jorgensen J, Shaw KR, Willman CL, Mullighan CG, Kantarjian H, Konopleva M. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood. 2017 02 02; 129(5):572-581. PMID: 27919910; PMCID: PMC5290985.
      Citations: 95     Fields:    Translation:HumansCells
    260. Jain N, O'Brien S. First-line therapy for young patients with CLL. Hematology Am Soc Hematol Educ Program. 2016 Dec 02; 2016(1):146-148. PMID: 27913473; PMCID: PMC6142430.
      Citations:    Fields:    Translation:HumansCells
    261. Chen Q, Jain N, Ayer T, Wierda WG, Flowers CR, O'Brien SM, Keating MJ, Kantarjian HM, Chhatwal J. Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. J Clin Oncol. 2017 Jan 10; 35(2):166-174. PMID: 27870563; PMCID: PMC5559889.
      Citations: 49     Fields:    Translation:Humans
    262. Jain N, O'Brien S. BCR inhibitor failure in CLL: an unmet need. Blood. 2016 11 03; 128(18):2193-2194. PMID: 27811187.
      Citations: 4     Fields:    Translation:Humans
    263. Issa GC, Kantarjian HM, Yin CC, Qiao W, Ravandi F, Thomas D, Short NJ, Sasaki K, Garcia-Manero G, Kadia TM, Cortes JE, Daver N, Borthakur G, Jain N, Konopleva M, Khouri I, Kebriaei P, Champlin RE, Pierce S, O'Brien SM, Jabbour E. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer. 2017 02 01; 123(3):459-467. PMID: 27696391; PMCID: PMC5321542.
      Citations: 18     Fields:    Translation:Humans
    264. Jabbour E, Short NJ, Jorgensen JL, Yilmaz M, Ravandi F, Wang SA, Thomas DA, Khoury J, Champlin RE, Khouri I, Kebriaei P, O'Brien SM, Garcia-Manero G, Cortes JE, Sasaki K, Dinardo CD, Kadia TM, Jain N, Konopleva M, Garris R, Kantarjian HM. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer. 2017 01 01; 123(2):294-302. PMID: 27602508; PMCID: PMC5321541.
      Citations: 29     Fields:    Translation:HumansCells
    265. Short NJ, Kantarjian HM, Sasaki K, Cortes JE, Ravandi F, Thomas DA, Garcia-Manero G, Khouri I, Kebriaei P, Champlin RE, Pierce S, Issa GC, Konopleva M, Kadia TM, Bueso-Ramos C, Khoury JD, Jain N, O'Brien SM, Jabbour E. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2016 Dec 15; 122(24):3812-3820. PMID: 27508525; PMCID: PMC5321530.
      Citations: 7     Fields:    Translation:HumansCells
    266. Agbay RL, Jain N, Loghavi S, Medeiros LJ, Khoury JD. Histologic transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol. 2016 10; 91(10):1036-43. PMID: 27414262.
      Citations: 11     Fields:    Translation:Humans
    267. Sasaki K, Jabbour EJ, Ravandi F, Short NJ, Thomas DA, Garcia-Manero G, Daver NG, Kadia TM, Konopleva MY, Jain N, Issa GC, Jeanis V, Moore HG, Garris RS, Pemmaraju N, Cortes JE, O'Brien SM, Kantarjian HM. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2016 Dec 01; 122(23):3650-3656. PMID: 27479888; PMCID: PMC5321539.
      Citations: 51     Fields:    Translation:HumansCellsCTClinical Trials
    268. Sasaki K, Popat U, Jain P, Kadia T, Patel K, Patel K, Jain N, Takahashi K, Young K, Miranda RN, Oo TH, Lu H, Pemmaraju N. Successful treatment of aplastic anemia-paroxysmal nocturnal hemoglobinuria associated with eosinophilic fasciitis with matched unrelated donor allogeneic peripheral blood stem cell transplantation. Clin Case Rep. 2016 Aug; 4(8):765-7. PMID: 27525080; PMCID: PMC4974424.
      Citations: 1     
    269. Jain N, Keating MJ. Richter transformation of CLL. Expert Rev Hematol. 2016 Aug; 9(8):793-801. PMID: 27351634.
      Citations: 6     Fields:    Translation:Humans
    270. Jain P, Kanagal-Shamanna R, Wierda W, Ferrajoli A, Keating M, Jain N. Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab. Hematol Oncol Stem Cell Ther. 2017 Sep; 10(3):151-154. PMID: 27352257; PMCID: PMC7001725.
      Citations: 4     Fields:    Translation:Humans
    271. Alhuraiji A, Jain N. Immunofluorescence staining with an antipromyelocytic leukemia antibody for a rapid diagnosis of acute promyelocytic leukemia. Hematol Oncol Stem Cell Ther. 2017 Mar; 10(1):33-34. PMID: 27362439.
      Citations:    Fields:    Translation:Humans
    272. Vitale C, Ahn IE, Sivina M, Ferrajoli A, Wierda WG, Estrov Z, Konoplev SN, Jain N, O'Brien S, Farooqui M, Keating MJ, Wiestner A, Burger JA. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2016 06; 101(6):e254-8. PMID: 27013651; PMCID: PMC5013951.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    273. Jain N, Steensma D, Stewart DJ, Kantarjian H. Insurance Denial of Coverage for Patients Enrolled in Cancer Clinical Trials Is Still a Problem in the Affordable Care Act Era. J Oncol Pract. 2016 Apr; 12(4):283-5. PMID: 26907450.
      Citations: 1     Fields:    Translation:Humans
    274. Short NJ, Kantarjian HM, Jabbour EJ, O'Brien SM, Faderl S, Burger JA, Garris R, Qiao W, Huang X, Jain N, Konopleva M, Kadia TM, Daver N, Borthakur G, Cortes JE, Ravandi F. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. Am J Hematol. 2016 Jun; 91(4):385-9. PMID: 26800008; PMCID: PMC5834229.
      Citations:    Fields:    Translation:Humans
    275. George B, Kantarjian H, Jabbour E, Jain N. Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia. Immunotherapy. 2016 Feb; 8(2):135-43. PMID: 26780449; PMCID: PMC5618942.
      Citations: 6     Fields:    Translation:Humans
    276. Jain N, Lamb AV, O'Brien S, Ravandi F, Konopleva M, Jabbour E, Zuo Z, Jorgensen J, Lin P, Pierce S, Thomas D, Rytting M, Borthakur G, Kadia T, Cortes J, Kantarjian HM, Khoury JD. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016 Apr 14; 127(15):1863-9. PMID: 26747249; PMCID: PMC4915808.
      Citations: 90     Fields:    Translation:HumansCells
    277. Miller JE, Higgins LD, Dong Y, Collins JE, Bean JF, Seitz AL, Katz JN, Jain NB. Association of Strength Measurement with Rotator Cuff Tear in Patients with Shoulder Pain: The Rotator Cuff Outcomes Workgroup Study. Am J Phys Med Rehabil. 2016 Jan; 95(1):47-56. PMID: 26098921; PMCID: PMC4713123.
      Citations: 10     Fields:    Translation:Humans
    278. Jain N, O'Brien S. Targeted therapies for CLL: Practical issues with the changing treatment paradigm. Blood Rev. 2016 05; 30(3):233-44. PMID: 26776345.
      Citations: 30     Fields:    Translation:Humans
    279. Luz J, Siddiqui I, Jain NB, Kohler MJ, Donovan J, Gerrard P, Borg-Stein J. Resident-Perceived Benefit of a Diagnostic and Interventional Musculoskeletal Ultrasound Curriculum: A Multifaceted Approach Using Independent Study, Peer Teaching, and Interdisciplinary Collaboration. Am J Phys Med Rehabil. 2015 Dec; 94(12):1095-103. PMID: 26098924; PMCID: PMC4710470.
      Citations: 11     Fields:    Translation:Humans
    280. Thompson PA, O'Brien SM, Xiao L, Wang X, Burger JA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG. ?2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. Cancer. 2016 Feb 15; 122(4):565-73. PMID: 26588193; PMCID: PMC4813299.
      Citations: 10     Fields:    Translation:HumansCells
    281. Ravandi F, Jorgensen JL, O'Brien SM, Jabbour E, Thomas DA, Borthakur G, Garris R, Huang X, Garcia-Manero G, Burger JA, Ferrajoli A, Wierda W, Kadia T, Jain N, Wang SA, Konoplev S, Kebriaei P, Champlin RE, McCue D, Estrov Z, Cortes JE, Kantarjian HM. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2016 Feb; 172(3):392-400. PMID: 26492205; PMCID: PMC4826052.
      Citations: 38     Fields:    Translation:Humans
    282. Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, Pemmaraju N, Daver N, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Yin CC, Khoury JD, Jorgensen J, Estrov Z, Bohannan Z, Konopleva M, Kadia T, Jain N, DiNardo C, Wierda W, Jeanis V, O'Brien S. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015 Nov; 16(15):1547-1555. PMID: 26432046; PMCID: PMC4816046.
      Citations: 83     Fields:    Translation:HumansCellsCTClinical Trials
    283. Thompson PA, O'Brien SM, Wierda WG, Ferrajoli A, Stingo F, Smith SC, Burger JA, Estrov Z, Jain N, Kantarjian HM, Keating MJ. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 2015 Oct 15; 121(20):3612-21. PMID: 26193999; PMCID: PMC4866653.
      Citations: 88     Fields:    Translation:HumansCells
    284. Jain N, O'Brien S. Initial treatment of CLL: integrating biology and functional status. Blood. 2015 Jul 23; 126(4):463-70. PMID: 26065656; PMCID: PMC4624441.
      Citations: 32     Fields:    Translation:Humans
    285. Jain NB, Ayers GD, Peterson EN, Harris MB, Morse L, O'Connor KC, Garshick E. Traumatic spinal cord injury in the United States, 1993-2012. JAMA. 2015 Jun 09; 313(22):2236-43. PMID: 26057284; PMCID: PMC4712685.
      Citations: 150     Fields:    Translation:Humans
    286. Curry EJ, Matzkin EE, Dong Y, Higgins LD, Katz JN, Jain NB. Structural Characteristics Are Not Associated With Pain and Function in Rotator Cuff Tears: The ROW Cohort Study. Orthop J Sports Med. 2015 May; 3(5):2325967115584596. PMID: 26675985; PMCID: PMC4622350.
      Citations: 15     
    287. Black EM, Lin A, Srikumaran U, Jain N, Freehill MT. Arthroscopic transosseous rotator cuff repair: technical note, outcomes, and complications. Orthopedics. 2015 May; 38(5):e352-8. PMID: 25970360; PMCID: PMC4712630.
      Citations: 11     Fields:    Translation:Humans
    288. Jain N. New developments in Richter syndrome. Clin Adv Hematol Oncol. 2015 Apr; 13(4):220-2. PMID: 26352579.
      Citations:    Fields:    Translation:Humans
    289. Rozovski U, Grgurevic S, Bueso-Ramos C, Harris DM, Li P, Liu Z, Wu JY, Jain P, Wierda W, Burger J, O'Brien S, Jain N, Ferrajoli A, Keating MJ, Estrov Z. Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells. Mol Cancer Res. 2015 May; 13(5):944-53. PMID: 25733697; PMCID: PMC4433415.
      Citations: 37     Fields:    Translation:Humans
    290. Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N, George B, James D, Kantarjian H, Burger J, O'Brien S. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015 Mar 26; 125(13):2062-7. PMID: 25573991; PMCID: PMC4467871.
      Citations: 121     Fields:    Translation:Humans
    291. Yin CC, Jain N, Mehrotra M, Zhagn J, Protopopov A, Zuo Z, Pemmaraju N, DiNardo C, Hirsch-Ginsberg C, Wang SA, Medeiros LJ, Chin L, Patel KP, Ravandi F, Futreal A, Bueso-Ramos CE. Identification of a novel fusion gene, IRF2BP2-RARA, in acute promyelocytic leukemia. J Natl Compr Canc Netw. 2015 Jan; 13(1):19-22. PMID: 25583766; PMCID: PMC5843191.
      Citations: 22     Fields:    Translation:HumansCells
    292. Mascarinas AL, Newman JS, Warner JJ, Jain NB. Ultrasound of the pectoralis major muscle after reverse shoulder arthroplasty: a case report. Am J Phys Med Rehabil. 2014 Dec; 93(12):e9-e14. PMID: 25251253; PMCID: PMC4237665.
      Citations:    Fields:    Translation:Humans
    293. Jain NB, Yamaguchi K. The contribution of reverse shoulder arthroplasty to utilization of primary shoulder arthroplasty. J Shoulder Elbow Surg. 2014 Dec; 23(12):1905-1912. PMID: 25304043; PMCID: PMC4252758.
      Citations: 29     Fields:    Translation:Humans
    294. Song A, Katz JN, Higgins LD, Newman J, Gomoll A, Jain NB. Outcomes of Ultrasound-guided Glen Humeral Corticosteroid Injections in Adhesive Capsulitis. Br J Med Med Res. 2014 Sep 25; 5(5):570-578. PMID: 27066399; PMCID: PMC4824683.
      Citations: 1     
    295. Jain NB, Losina E, Collins J, Newman JS, Katz JN, Higgins LD. Reliability of magnetic resonance imaging assessment of rotator cuff: the ROW study. PM R. 2015 Mar; 7(3):245-54.e3; quiz 254. PMID: 25180471; PMCID: PMC4345160.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    296. Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Baladandayuthapani V, Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K, Daver N, Nazha A, Verstovsek S, Jabbour E, De Lima M, Champlin R, Cortes J, Qazilbash MH, Nogueras Gonz?lez GM. Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Feb; 15(2):110-4. PMID: 25107338; PMCID: PMC4294996.
      Citations: 15     Fields:    Translation:Humans
    297. Song A, Higgins LD, Newman J, Jain NB. Glenohumeral corticosteroid injections in adhesive capsulitis: a systematic search and review. PM R. 2014 Dec; 6(12):1143-56. PMID: 24998406; PMCID: PMC4268082.
      Citations: 21     Fields:    Translation:Humans
    298. Strati P, Keating MJ, O'Brien SM, Ferrajoli A, Burger J, Faderl S, Tambaro FP, Jain N, Wierda WG. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica. 2014 Aug; 99(8):1350-5. PMID: 24859876; PMCID: PMC4116834.
      Citations: 29     Fields:    Translation:HumansCells
    299. Rozovski U, Wu JY, Harris DM, Liu Z, Li P, Hazan-Halevy I, Ferrajoli A, Burger JA, O'Brien S, Jain N, Verstovsek S, Wierda WG, Keating MJ, Estrov Z. Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood. 2014 Jun 12; 123(24):3797-802. PMID: 24778152; PMCID: PMC4055926.
      Citations: 39     Fields:    Translation:HumansCells
    300. Strati P, Keating MJ, O'Brien SM, Burger J, Ferrajoli A, Jain N, Estrov Z, Jorgensen J, Challagundla P, Faderl SH, Wierda WG, Tambaro FP. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood. 2014 Jun 12; 123(24):3727-32. PMID: 24705492; PMCID: PMC4067501.
      Citations: 45     Fields:    Translation:HumansCTClinical Trials
    301. Pemmaraju N, Shetty AV, Prieto VG, Jain N, Kontoyiannis DP, Borthakur G. Disseminated Saprochaete capitata (formerly known as Geotrichum capitatum and Blastoschizomyces capitatus) in a patient with acute myeloid leukemia. Eur J Haematol. 2014 Dec; 93(6):543-4. PMID: 24592915.
      Citations: 6     Fields:    Translation:HumansAnimals
    302. Falchi L, Keating MJ, Marom EM, Truong MT, Schlette EJ, Sargent RL, Trinh L, Wang X, Smith SC, Jain N, Estrov Z, O'Brien S, Wierda WG, Lerner S, Ferrajoli A. Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood. 2014 May 01; 123(18):2783-90. PMID: 24615780; PMCID: PMC4123418.
      Citations: 38     Fields:    Translation:Humans
    303. DiNardo CD, Daver N, Jain N, Pemmaraju N, Bueso-Ramos C, Yin CC, Pierce S, Jabbour E, Cortes JE, Kantarjian HM, Garcia-Manero G, Verstovsek S. Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy. Leukemia. 2014 Apr; 28(4):958-61. PMID: 24492324; PMCID: PMC3981947.
      Citations: 19     Fields:    Translation:Humans
    304. Jain NB, Higgins LD, Losina E, Collins J, Blazar PE, Katz JN. Epidemiology of musculoskeletal upper extremity ambulatory surgery in the United States. BMC Musculoskelet Disord. 2014 Jan 08; 15:4. PMID: 24397703; PMCID: PMC3893587.
      Citations: 60     Fields:    Translation:Humans
    305. Jain N, O'Brien S, Thomas D, Kantarjian H. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia. Front Biosci (Elite Ed). 2014 01 01; 6(1):40-5. PMID: 24389139.
      Citations: 6     Fields:    Translation:Humans
    306. Jain NB, Yamaguchi K. History and physical examination provide little guidance on diagnosis of rotator cuff tears. Evid Based Med. 2014 Jun; 19(3):108. PMID: 24347201; PMCID: PMC4709248.
      Citations: 6     Fields:    Translation:Humans
    307. Jain N, Khoury JD, Pemmaraju N, Kollipara P, Kantarjian H, Verstovsek S. Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement. Blood. 2013 Nov 07; 122(19):3387-8. PMID: 24203930.
      Citations: 1     Fields:    Translation:Humans
    308. Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison T, Erba HP, Green M, Poire X, Koval G, Shannon K, Reddy PL, Joseph L, Atallah EL, Dy P, Thomas SP, Smith SE, Doyle LA, Stadler WM, Larson RA, Stock W, Odenike O. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2014 Jan 15; 20(2):490-8. PMID: 24178622; PMCID: PMC4310865.
      Citations: 59     Fields:    Translation:HumansCTClinical Trials
    309. Neuhaus V, Bot AG, Swellengrebel CH, Jain NB, Warner JJ, Ring DC. Treatment choice affects inpatient adverse events and mortality in older aged inpatients with an isolated fracture of the proximal humerus. J Shoulder Elbow Surg. 2014 Jun; 23(6):800-6. PMID: 24135421; PMCID: PMC4239693.
      Citations: 17     Fields:    Translation:Humans
    310. Jain N, O'Brien S. The frontline treatment of chronic myeloid leukemia in the chronic phase: current clinical decisions and future prospects for treatment. Expert Rev Hematol. 2013 Oct; 6(5):575-86. PMID: 24083594.
      Citations: 5     Fields:    Translation:Humans
    311. Alayed K, Patel KP, Konoplev S, Singh RR, Routbort MJ, Reddy N, Pemmaraju N, Zhang L, Shaikh AA, Aladily TN, Jain N, Luthra R, Medeiros LJ, Khoury JD. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013 Dec; 88(12):1055-61. PMID: 23940084.
      Citations: 43     Fields:    Translation:HumansCells
    312. Jain N, O'Brien S. Ibrutinib (PCI-32765) in chronic lymphocytic leukemia. Hematol Oncol Clin North Am. 2013 Aug; 27(4):851-60, x. PMID: 23915749; PMCID: PMC4449150.
      Citations: 7     Fields:    Translation:Humans
    313. Jain N, Liu H, Artz AS, Anastasi J, Odenike O, Godley LA, Joseph L, Marino S, Kline J, Nguyen V, Schouten V, Kunnavakkam R, Larson RA, Stock W, Ulaszek J, Savage PA, Wickrema A, van Besien K. Immune reconstitution after combined haploidentical and umbilical cord blood transplant. Leuk Lymphoma. 2013 Jun; 54(6):1242-9. PMID: 23088744.
      Citations: 9     Fields:    Translation:HumansCells
    314. Hossain NM, Jain N, Steinmetz JL, McConville JF, Anastasi J, Odenike O. A 32-year-old man with persistent cough, shortness of breath, eosinophilic pneumonia, and peripheral blood eosinophilia. Myeloid neoplasm associated with eosinophilia and platelet-derived growth factor receptor-alpha rearrangement. Chest. 2012 Dec; 142(6):1680-1683. PMID: 23208343.
      Citations: 2     Fields:    Translation:Humans
    315. Van Besien K, Liu H, Jain N, Stock W, Artz A. Umbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications. Biol Blood Marrow Transplant. 2013 May; 19(5):682-91. PMID: 23142329; PMCID: PMC3618995.
      Citations: 15     Fields:    Translation:Humans
    316. Jain N, O'Brien S. Chronic lymphocytic leukemia with deletion 17p: emerging treatment options. Oncology (Williston Park). 2012 Nov; 26(11):1067, 1070. PMID: 23330347.
      Citations: 6     Fields:    Translation:HumansCells
    317. Jain NB. Joint replacement costs in the era of healthcare reform: commentary on an article by James C. Robinson, PhD, MPH, et al.: ?Variability in costs associated with total hip and knee replacement implants?. J Bone Joint Surg Am. 2012 Sep 19; 94(18):e140(1-2). PMID: 22878364; PMCID: PMC3444950.
      Citations: 1     Fields:    Translation:Humans
    318. Jain NB, Kuye I, Higgins LD, Warner JJ. Surgeon volume is associated with cost and variation in surgical treatment of proximal humeral fractures. Clin Orthop Relat Res. 2013 Feb; 471(2):655-64. PMID: 22826013; PMCID: PMC3549192.
      Citations: 9     Fields:    Translation:Humans
    319. Jain N, van Besien K. Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era. Hematol Oncol Clin North Am. 2011 Oct; 25(5):1025-48, vi. PMID: 22054733; PMCID: PMC3246008.
      Citations: 5     Fields:    Translation:Humans
    320. Kuye IO, Jain NB, Warner L, Herndon JH, Warner JJ. Economic evaluations in shoulder pathologies: a systematic review of the literature. J Shoulder Elbow Surg. 2012 Mar; 21(3):367-75. PMID: 21865060; PMCID: PMC3783003.
      Citations: 13     Fields:    Translation:Humans
    321. Jain N, Verstovsek S, Quint?s-Cardama A. Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis. Cancer. 2011 Dec 15; 117(24):5439-49. PMID: 21692073; PMCID: PMC4839285.
      Citations: 9     Fields:    Translation:HumansAnimals
    322. Jain N, Odenike O. Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies. Expert Opin Pharmacother. 2010 Dec; 11(18):3073-84. PMID: 21080855.
      Citations: 3     Fields:    Translation:HumansAnimals
    323. Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G, Kennedy D, Estrov Z, Cortes J, Verstovsek S. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood. 2010 Feb 11; 115(6):1131-6. PMID: 20008298; PMCID: PMC4081385.
      Citations: 78     Fields:    Translation:HumansCTClinical Trials
    324. Jain N, Wierda W, Ferrajoli A, Wong F, Lerner S, Keating M, O'Brien S. A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia. Cancer. 2009 Oct 01; 115(19):4533-9. PMID: 19637351; PMCID: PMC4535918.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    325. Weisskopf MG, Jain N, Nie H, Sparrow D, Vokonas P, Schwartz J, Hu H. A prospective study of bone lead concentration and death from all causes, cardiovascular diseases, and cancer in the Department of Veterans Affairs Normative Aging Study. Circulation. 2009 Sep 22; 120(12):1056-64. PMID: 19738141; PMCID: PMC2760410.
      Citations: 53     Fields:    Translation:HumansPHPublic Health
    326. Jain N, Reuben JM, Kantarjian H, Li C, Gao H, Lee BN, Cohen EN, Ebarb T, Scheinberg DA, Cortes J. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer. 2009 Sep 01; 115(17):3924-34. PMID: 19536894; PMCID: PMC5534348.
      Citations: 24     Fields:    Translation:HumansCellsCTClinical Trials
    327. Jain N, Lamanna N. Incorporating prognostic information into treatment decisions in chronic lymphocytic leukemia. Curr Oncol Rep. 2009 Sep; 11(5):353-9. PMID: 19679010.
      Citations:    Fields:    Translation:HumansCells
    328. Sever M, Kantarjian H, Pierce S, Jain N, Estrov Z, Cortes J, Verstovsek S. Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation. Int J Hematol. 2009 Nov; 90(4):522-525. PMID: 19728024; PMCID: PMC4209590.
      Citations: 4     Fields:    Translation:Humans
    329. Borthakur G, Lin E, Jain N, Estey EE, Cortes JE, O'Brien S, Faderl S, Ravandi F, Pierce S, Kantarjian H. Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. Cancer. 2009 Jul 15; 115(14):3217-21. PMID: 19441109; PMCID: PMC4184418.
      Citations: 22     Fields:    Translation:Humans
    330. Fava C, Kantarjian HM, Jabbour E, O'Brien S, Jain N, Rios MB, Garcia-Manero G, Ravandi F, Verstovsek S, Borthakur G, Shan J, Cortes J. Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood. 2009 May 21; 113(21):5058-63. PMID: 19282457; PMCID: PMC4081366.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    331. Jain N, Cortes J, Manshouri T, Luthra R, Garcia-Manero G, Kantarjian H, Verstovsek S, Quint?s-Cardama A. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. Leuk Res. 2009 Jun; 33(6):837-9. PMID: 19013640; PMCID: PMC4422052.
      Citations: 11     Fields:    Translation:Humans
    332. Jain N, Rossi A, Garcia-Manero G. Epigenetic therapy of leukemia: An update. Int J Biochem Cell Biol. 2009 Jan; 41(1):72-80. PMID: 18948224; PMCID: PMC3833715.
      Citations: 23     Fields:    Translation:HumansCells
    333. Verma D, Kantarjian H, Jain N, Cortes J. Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha. Leuk Lymphoma. 2008 Jul; 49(7):1399-402. PMID: 18452066.
      Citations: 8     Fields:    Translation:Humans
    334. Morse LR, Stolzmann K, Nguyen HP, Jain NB, Zayac C, Gagnon DR, Tun CG, Garshick E. Association between mobility mode and C-reactive protein levels in men with chronic spinal cord injury. Arch Phys Med Rehabil. 2008 Apr; 89(4):726-31. PMID: 18374004; PMCID: PMC2365500.
      Citations: 21     Fields:    Translation:Humans
    335. Jain N, Fisk D, Sotir M, Kehl KS. West Nile encephalitis, status epilepticus and West Nile pneumonia in a renal transplant patient. Transpl Int. 2007 Sep; 20(9):800-3. PMID: 17630998.
      Citations: 5     Fields:    Translation:HumansCells
    336. Jain N, Patel D, Pfeifer KJ. Vertebral osteomyelitis in a healthy young adult. WMJ. 2007 May; 106(3):152-4. PMID: 17642354.
      Citations: 1     Fields:    Translation:Humans
    337. Jain NB, Potula V, Schwartz J, Vokonas PS, Sparrow D, Wright RO, Nie H, Hu H. Lead levels and ischemic heart disease in a prospective study of middle-aged and elderly men: the VA Normative Aging Study. Environ Health Perspect. 2007 Jun; 115(6):871-5. PMID: 17589593; PMCID: PMC1892138.
      Citations: 32     Fields:    Translation:Humans
    338. Jain NB, Hart JE, Smith TJ, Garshick E, Laden F. Smoking behavior in trucking industry workers. Am J Ind Med. 2006 Dec; 49(12):1013-20. PMID: 17096359; PMCID: PMC1945044.
      Citations: 15     Fields:    Translation:HumansPHPublic Health
    339. Jain NB, Brown R, Tun CG, Gagnon D, Garshick E. Determinants of forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/FVC in chronic spinal cord injury. Arch Phys Med Rehabil. 2006 Oct; 87(10):1327-33. PMID: 17023241; PMCID: PMC1896316.
      Citations: 24     Fields:    Translation:Humans
    340. Elmarsafawy SF, Jain NB, Schwartz J, Sparrow D, Nie H, Hu H. Dietary calcium as a potential modifier of the relationship of lead burden to blood pressure. Epidemiology. 2006 Sep; 17(5):531-7. PMID: 16878040.
      Citations: 7     Fields:    Translation:Humans
    341. Jain NB, Higgins LD, Guller U, Pietrobon R, Katz JN. Trends in the epidemiology of total shoulder arthroplasty in the United States from 1990-2000. Arthritis Rheum. 2006 Aug 15; 55(4):591-7. PMID: 16874781.
      Citations: 34     Fields:    Translation:Humans
    342. Jain NB, Hu H. Childhood correlates of blood lead levels in Mumbai and Delhi. Environ Health Perspect. 2006 Mar; 114(3):466-70. PMID: 16507473; PMCID: PMC1392244.
      Citations: 20     Fields:    Translation:HumansPHPublic Health
    343. Jain NB, Higgins LD, Ozumba D, Guller U, Cronin M, Pietrobon R, Katz JN. Trends in epidemiology of knee arthroplasty in the United States, 1990-2000. Arthritis Rheum. 2005 Dec; 52(12):3928-33. PMID: 16320340.
      Citations: 62     Fields:    Translation:Humans
    344. Jain NB, Hocker S, Pietrobon R, Guller U, Bathia N, Higgins LD. Total arthroplasty versus hemiarthroplasty for glenohumeral osteoarthritis: role of provider volume. J Shoulder Elbow Surg. 2005 Jul-Aug; 14(4):361-7. PMID: 16015234.
      Citations: 8     Fields:    Translation:Humans
    345. Jain N, Pietrobon R, Hocker S, Guller U, Shankar A, Higgins LD. The relationship between surgeon and hospital volume and outcomes for shoulder arthroplasty. J Bone Joint Surg Am. 2004 Mar; 86(3):496-505. PMID: 14996874.
      Citations: 60     Fields:    Translation:Humans
    346. Prasad K, Singhal T, Jain N, Gupta PK. Third generation cephalosporins versus conventional antibiotics for treating acute bacterial meningitis. Cochrane Database Syst Rev. 2004; (2):CD001832. PMID: 15106163.
      Citations:    Fields:    Translation:Humans
    347. An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes. OncoTargets and Therapy. 3:1-13.
    348. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia.
    349. Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia. Immunotherapy. 8:135-143.
    350. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults. Blood. 127:1863-1869.
    351. Insurance denial of coverage for patients enrolled in cancer clinical trials is still a problem in the affordable care act era. Journal of Oncology Practice. 12:283-285.
    352. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer.
    353. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer.
    354. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer.
    355. BCR inhibitor failure in CLL. Blood. 128:2193-2194.
    356. Dorsal column myelopathy after intrathecal chemotherapy for leukemia. American Journal of Hematology. 92:155-160.
    357. Aberrant LPL expression, driven by STAT3, Mediates free fatty acid metabolism in cll cells. Molecular Cancer Research. 13:944-953.
    358. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 101:e254-e258.
    359. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia. The Lancet Haematology.
    360. Richter transformation of CLL. Expert Review of Hematology. 9:793-801.
    361. Systemic mastocytosis. Drugs of the Future. 33:187-192.
    362. β2-microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. Cancer. 122:565-573.
    363. Chronic lymphocytic leukemia with deletion 17p. ONCOLOGY (United States). 26.
    364. New developments in Richter syndrome. Clinical Advances in Hematology and Oncology. 13:220-222.
    365. Targeted therapies for CLL. Blood Reviews.
    366. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. British Journal of Haematology.
    367. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia. The Lancet Oncology. 16:1547-1555.
    368. Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia. Hematology/ Oncology and Stem Cell Therapy.
    369. Management of B-Cell Acute Lymphoblastic Leukemia. 22-28.
    370. Proceedings from the 2007 Annual Meeting of the American College of Physicians, Wisconsin Chapter. Wisconsin Medical Journal. 107:247-262.
    371. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. American Journal of Hematology.
    372. Immunofluorescence staining with an antipromyelocytic leukemia antibody for a rapid diagnosis of acute promyelocytic leukemia. Hematology/ Oncology and Stem Cell Therapy.
    373. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 121:3612-3621.
    374. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer.
    JAIN's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (738)
    Explore
    _
    Co-Authors (130)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _